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Highly active anti-retroviral therapy (HAART) has been successful in delaying the 
progression to AIDS in HIV infected individuals. Exposure to HAART can result in metabolic 
side effects such as dyslipidemia and lipodystrophy in a subset of treated patients. We used a 
custom designed Illumina GoldenGate Genotyping assay to investigate the genetic susceptibility 
to dyslipidemia attributed to HIV infection and HAART treatment. 1,945 men were selected 
from the Multicenter AIDS Cohort Study (MACS) for genotyping and phenotypic analysis of 
serum lipid levels. This population was stratified by biogeographical ancestry and HIV/HAART 
status. Among men of European ancestry, those who were infected with HIV and receiving 
HAART had significantly lower serum low-density lipoprotein cholesterol (LDL-C, P = 1.90 
x10-4) and high-density lipoprotein cholesterol levels (HDL-C, P < 1.00 x10-7), with significantly 
higher serum triglyceride (TRIG, P < 1.00 x10-7) levels compared to HIV/HAART (-/-) controls. 
Among men of mixed African and European ancestry, those who were HIV/HAART (+/+) had 
significantly lower LDL-C (P = 1.80 x10-4) levels compared to HIV/HAART (-/-) controls. Four 
SNPs; rs1532624 (P = 1.66 x10-5), rs1532625 (P = 2.36 x10-5), rs711752 (P = 4.48 x10-5), and 
rs708272 (P = 4.59 x10-5), located in the CETP gene region on chromosome 16 had statistically 
significant associations with serum HDL-C levels in HIV/HAART (+/+) European men. One 
SNP, rs261334 (P = 6.53 x10-6), located in the LIPC gene region on chromosome 15 was 
associated with serum LDL-C levels and another SNP, rs4783961 (P = 9.83 x10-6) located in the 
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CETP gene region, was associated with HDL-C levels in HIV/HAART (+/+) men of mixed 
African and European ancestry. These results show that dyslipidemia attributed to HAART 
varies depending on biogeographical ancestry and implicates two genes associated with serum 
lipid levels in these patients. Understanding the mechanism of HAART-associated dyslipidemia 
is important to global public health because nearly half of the estimated 30 million individuals 
infected with HIV are receiving or eligible to receive these drugs and are at risk of these HAART 
related side effects. Our results can also aid in identifying those individuals at greatest risk of 
developing HAART-associated dyslipidemia, which could improve monitoring and management 
of care given to these patients. 
 vi 
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Table 1 - Abbreviations 
Table of Abbreviations 
  
Acronym Meaning 
(-/-) HIV negative / HAART naïve 
(+/-) HIV positive / HAART naïve 
(+/+) HIV positive / HAART positive 
ADT Assay design tool 
AEA African and European ancestry 
AIDS Acquired Immunodeficiency Syndrome 
AIM Ancestry Informative Markers 
ANOVA Analysis of Variance 
APOA5 Apolipoprotein A-V  
APOB Apolipoprotein B  
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ASW African ancestry in southwest USA 
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BUD13 BUD13 homolog 
CAC Coronary Artery Calcification 
CAD Coronary Artery Disease 
CAMACS Center for the Analysis and Management of the Multicenter AIDS Cohort Study 
CCR5 C-C Chemokine Receptor Type 5 
CD4 Cluster of Differentiation 4 
CETP Cholesteryl ester transfer protein 
CEU Utah residents with ancestry from northern and western Europe 
CHD Chinese in Metropolitan Denver 
CHD Coronary Heart Disease 
CNV Copy number variation 
CRF Circulating Recombinant Forms 
CRP C-reactive protein 
CT Computed Tomography 
CVD Cardiovascular Disease 
CXCR4 C-X-C Chemokine Receptor Type 4 
D:A:D Data Collection on Adverse Events of Anti-HIV Drugs 
DC-SIGN Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin 
DNA Deoxyribonucleic Acid 




FDA Food and Drug Administration 
FDR False Discovery Rate 
FP Fluorescent Polarization  
GALT Gut Associated Lymphatic Tissue 
GC GenCall 
GLM Generalize linear model 
gp Glycoprotein 
GPCL Genomics and Proteomics Core Laboratories  
GWAS Genome-wide association study 
HAART Highly Active Antiretroviral Therapy 
HDL-C High-density lipoprotein cholesterol 
HIV Human Immunodeficiency Virus 
HLA Human Leukocyte Antigen 
HMG-CoA  3-hydroxy-3-methyl-glutaryl-CoA reductase 
IBS Identity-by-State 
IMT Intima-media Thickness 
LD Linkage disequilibrium 
LDL-C Low-density lipoprotein cholesterol 
LDLR LDL receptor 
LIPC Lipase, hepatic 
LSO Locus-specific oligo 
LTR Long Terminal Repeat 
MACS Multicenter AIDS Cohort Study 
MAF Minor allele frequency 
MDS Multidimensional Scaling 
MEX Mexican ancestry in Los Angeles 
mHDL-C mean HDL-C 
MI Myocardial Infarction 
mLDL-C mean LDL-C 
mRNA Messenger RNA 
MSM Men who have sex with men 
mTCHOL mean TCHOL 
mTRIG mean TRIG 
Nef Negative Regulatory Factor 
NNRTI Non-nucleoside reverse transcriptase inhibitor 
NRTI Nucleoside analog reverse transcriptase inhibitor 
PBMC Peripheral Blood Mononuclear Cells 
PCR Polymerase Chain Reaction 
PI Protease inhibitor 
Pol Polymerase 
QC Quality control 
QQ-plot Quantile-Quantile plot 
 xiv 
Acronym Meaning 
RCT Reverse Cholesterol Transport 
RNA Ribonucleic Acid 
RT Reverse Transcriptase 
SIV Simian Immunodeficiency Virus 
SMAC Supramolecular activation clusters 
SNP Single nucleotide polymorphism 
SREBP2 Sterol regulatory element binding transcription factor 2 
ss Single Stranded 
SRR Self-Reported Race 
T-Cell T Lymphocyte 
Tat Trans-activator of Transcription 
TCHOL Total cholesterol 
TRIG Triglycerides 
TukeyHSD Tukey's Honestly Significant Difference test 
UTR Untranslated region 
Vif Viral Infectivity Factor 
VLDL Very-low density lipoprotein 
Vpr Viral Protein R 
Vpu Viral Protein U 
WGA Whole genome amplification 
WnH White non-Hispanic 
YRI Yoruba in Ibadan, Nigeria 
ZNF259 Zinc finger protein 259 
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1.0  INTRODUCTION 
 
1.1 HUMAN IMMUNODEFICIENCY VIRUS 
1.1.1 History and Epidemiology 
In June 1981 the Centers for Disease Control and Prevention (CDC) published a report of five 
homosexual men with Pneumocystis pneumonia in Los Angeles, California1. In July and August 
of that year the CDC published two more Morbidity and Mortality Weekly Reports (MMWR) 
papers that reported additional cases of Pneumocystis pneumonia and Kaposi’s Sarcoma in 
homosexual men from New York City and California2,3. These three reports would be the first to 
identify patients suffering from an infectious disease that would become the most significant 
public health issue of the 20th century. 
Pneumocystis pneumonia and Kaposi’s Sarcoma are extremely rare diseases that are 
usually only seen in people with severely impaired immune systems. All of the patients 
identified in the MMWR reports lacked any known underlying condition that would explain this 
immunodeficiency. A CDC task force found a pattern of shared symptoms in these cases: low 
CD4+ T-cell counts, lymphadenopathy, and recurrent opportunistic infections. They would come 
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to name this condition Acquired Immune Deficiency Syndrome, AIDS. It was soon observed that 
a similar syndrome existed in hemophiliacs and blood transfused patients4. The hemophiliacs 
gave the first clue to the causative agent of AIDS. These patients received purified blood 
products, factor 8 or 9, from pooled blood donors for treatment of their hemophilia. These blood 
products are filtered to remove any bacterial or fungal contaminates and any soluble toxic 
compounds, which suggested the possibility of a viral agent.  In 1983 two groups isolated this 
virus simultaneously. After some controversy, it was agreed to call this newly discovered virus 
Human Immunodeficiency Virus (HIV)5,6. 
In the 30 years since the first reports of AIDS in the United States, HIV has spread to 
every corner of the globe, currently infecting approximately 33 million people (Figure 1)7. The 
 
Figure 1 - Global Prevalence of HIV, 2009 
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global AIDS pandemic has essentially stabilized with rates of newly infected people declining 
since 1997 when new infections peaked at approximately 3.2 million. This decrease can be 
attributed to improved surveillance, prevention and education. However, not all countries are 
following this global trend of decreasing HIV incidence rates.  AIDS related deaths are also on 
the decline, from a peak in 2004 at approximately 2.1 million to an estimated 1.8 million in 
2009. This decrease can be attributed to increased availability of antiretroviral drugs and 
improved care of people living with HIV infection. The use of antiretroviral therapy, specifically 
highly active antiretroviral therapy (HAART), has altered the natural course of HIV infection 
and the progression to AIDS. HAART was established as the standard treatment for people 
infected with HIV in the late 90’s. HAART consists of a combination of multiple antiretroviral 
drugs that inhibit different stages of the HIV life cycle. While there is currently no cure for HIV 
infection, HAART has extended the time by which HIV infection progresses to AIDS by over a 
decade. Globally, the number of HIV infected people receiving antiretroviral therapy has 
expanded 13-fold since 2004. This has contributed to the 19% decline in annual HIV related 
deaths since 2004.  
With the prolonged lifespan of HIV infected individuals and the increasing number of 
patients receiving HAART, concerns have arisen regarding the side effects and potential health 
risks associated with long-term exposure to these drugs. HAART can result in metabolic 
disturbances such as insulin resistance, hypertriglyceridemia, hypercholesterolemia and 
morphologic changes pertaining to body fat distribution (lypodystrophy). These side effects are 
of particular concern because they resemble metabolic syndrome X, a combination of similar 
conditions seen in the HIV negative population that are significant cardiovascular disease risk 
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factors8. A subset of individuals receiving HAART experience drug related side effects, which 
suggests there may be a pre-existing genetic susceptibility present in these patients.  
1.1.2 Biology & Infection 
HIV is a Lentivirus in the family Retroviridae. Viruses in the family Retroviridae posses a RNA 
genome and utilize reverse transcriptase (RT), an RNA-dependent DNA polymerase, to 
synthesize a double-stranded DNA copy of the RNA viral genome during its infection cycle. The 
viruses in the genus Lentivirus are associated with long incubation times and are often called 
slow viruses. HIV is an enveloped virus with a single-stranded positive-sense RNA genome 
approximately 10kb long that codes for three structural polyproteins common to all retroviruses 
(Gag, Pol, and Env) and auxiliary proteins it uses for regulatory and accessory functions (Tat and 
Rev & Nef, Vif, Vpr, and Vpu, respectively). There are two types of HIV; HIV-1, which is the 
most prevalent globally, and HIV-2, which predominates mostly in West Africa. HIV-1 contains 
three major groups based on nucleotide sequence analysis; group M that includes most HIV-1 
isolates and groups O and N, which represent rare outlier viruses. HIV-1 group M viruses can be 
broken up into ten distinct subtypes called clades, A to K. These clades are often distributed by 
geographical location. Coinfection of an individual with different subtypes can lead to 
circulating recombinant forms (CRFs). It is believed that HIV-1 and -2 are zoonotic infections 
that originated from nonhuman primates in Africa. Specifically, sequence analysis of HIV-1 
shows that it is highly homologous to Simian Immunodeficiency Virus (SIVcpz) isolated from 
chimpanzees and HIV-2 has a high homology with SIVsmm strains isolated from sooty 
mangabeys9,10. SIV strains are often used to infect Asian macaques to create an AIDS-like 
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disease model used for research, but wild-type SIV strains that infect the chimpanzee and sooty 
mangabey are well tolerated and do not result in an AIDS-like syndrome. 
HIV can infect a variety of immune cells, principally through the interaction of the viral 
envelope protein gp160 (a dimmer of the gp120 + gp41 peptides) and cellular surface 
receptors11. (Figure 2) HIV requires two cellular receptors for viral fusion and entry; CD4 as its 
primary host receptor, and either CCR5 or CXCR4 as coreceptors. The use of specific 
 
Figure 2 - HIV Lifecycle 
 
 6 
coreceptors gives HIV its tropism, or selectivity for infecting certain cells; CCR5-tropic viruses 
predominately infect macrophages, and are often called Macrophage-tropic strains, whereas 
CXCR4-tropic viruses are called T-cell-line tropic strains. Mucosal infection of HIV-1 primarily 
occurs from CCR5-tropic viruses and progression to AIDS is often associated with a switch from 
CCR5 to CXCR4 tropic strains within an individual12. After viral fusion and uncoating the HIV-
1 genome is released into the host cytoplasm and the ss(+)RNA is reverse transcribed by RT into 
a double-stranded DNA provirus. The proviral genome is then translocated to the nucleus by the 
viral integrase protein (a cleavage product of the Pol polyprotein) and is integrated into the host 
chromosome. The long-terminal repeats (LTR) in the integrated proviral genome contain 
enhancer and regulatory elements that allow for full-length viral RNA to be transcribed by host 
transcription factors with help from the viral accessory protein Tat. These full-length RNA 
transcripts are either alternatively spliced into viral messenger RNA (mRNA) or remain as full-
length RNA that becomes packaged into new viral particles, serving as the viral genome for the 
next generation of progeny HIV. Some of the viral mRNA enters the cytoplasm to be translated 
by host ribosomes into the Gag-Pol precursor polyprotein, which is then proteolytically cleaved 
into the capsid, matrix, RT and integrase proteins. These viral proteins then form a complex and 
translocate to the inner surface of the host plasma membrane for viral assembly. Other viral 
mRNA molecules enter the endoplasmic reticulum where they are translated into the Env-
polyprotein precursor. The Env proteins are transported into the Golgi apparatus to be 
glycosylated and cleaved to form mature viral Env proteins, which are then delivered to the host 
plasma membrane for viral particle assembly. The viral components assemble at the host plasma 
membrane and then bud from the infected cell. After budding, viral proteases cleave specific 
sites on the Gag and Gag-Pol precursors to produce a mature and infectious virion. 
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HIV-1 is transmitted primarily via unprotected sexual contact, via blood, and from 
mother to child. The predominant routes of transmission differ by geographical region. In the 
United States HIV transmission is predominately by men who have sex with men (MSM) and by 
intravenous drug use. In contrast, transmission is mostly by heterosexual contact in the rest of the 
world. CCR5 tropic HIV enters the host through genital or rectal mucosal surfaces. The exact 
mechanism of viral translocates across the mucosal surface is not known. It is thought that, 
amongst a pool of HIV viruses that are exposed to the mucosal surface during sexual intercourse, 
most infections start with the crossing of very few ‘seed’ viruses13,14. Once HIV has crossed the 
mucosa it must find permissive cells to infect. The primary targets for HIV are activated cells 
expressing the CD4 surface receptor, e.g. activated CD4+ T-Cells located at the genital or rectal 
mucosa. HIV can also be bound and phagocytized by Dendritic cells through their surface 
receptor DC-SIGN. These dendritic cells are not actively infected by HIV, but act as a 
transporter to lymphatic tissues present at the site of infection, such as Peyer’s patches or 
peripheral lymph nodes where HIV is brought into contact with an abundance of activated CD4+ 
cells. HIV establishes local sites of infection at these lymphoid tissues because there is a large 
pool of cells for it to infect, resulting in lymphadenopathy and loss of gut associated lymphatic 
tissues (GALT) in acutely infected individuals15.  
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The course of HIV-1 infection is shown in Figure 3, and is characterized by three distinct stages; 
the acute phase, asymptomatic phase (latent phase) and the symptomatic phase (AIDS)16. During 
the acute phase of infection viral RNA copies in the plasma peak with an associated drop in 
CD4+ T-cell count. During this stage of infection viral replication is extremely high with up to 
1x1010 virions being produced per day17. As the adaptive immune response increases the host 
begins to control infection resulting in a decrease in plasma viral load and an increase in CD4+ 
 
Figure 3 - HIV Infection 
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T-cells. This leads to the second stage of infection, the asymptomatic phase, lasting years where 
plasma viral loads stay low along with a progressive loss of CD4+ T-cells. The steady-state 
viremia during this stage of infection predicts how quickly the host will progress to AIDS18. HIV 
infected individuals begin to experience symptoms of AIDS when serum CD4+ T-cell levels 
drop below 200 cells per µl. This drop is associated with increased plasma viral load and loss of 
HIV specific CD8+ T-cells. The loss of these immune cells results in the immunodeficiency, and 
inability to fight opportunistic infections that is the hallmark of individuals with AIDS.  
1.1.3 Antiretroviral Therapy 
While there is still no cure for HIV infection, the use of antiretroviral drugs has greatly altered 
the natural course of disease progression. Zidovudine (AZT) was the first drug to be used in the 
Unites States for the treatment of AIDS. AZT was first used in 1987 as an antiretroviral drug but 
was initially developed as a potential anticancer drug. AZT was the first of a class of drugs 
known as, nucleoside analog reverse transcriptase inhibitors (NRTI). NRTIs inhibit the function 
of RT by competing with the cellular deoxynucleosides used during reverse transcription. NRTIs 
are incorporated into the viral replication products resulting in chain-termination due to the 
presence of the azido group in AZT. As soon as 6 months after AZT was implemented as a 
treatment for AIDS, viruses could be isolated from patients whose RT had become resistant to 
AZT inhibition19. HIV is able to develop these resistance mutations so quickly due to the high 
rate of replication and error-prone nature of RT itself. RT, unlike other DNA polymerases, lacks 
proofreading capability, resulting in a large amount of misincorporation – approximately 1 error 
for every 2000-5000 polymerized nucleotides20. 
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With the development of AZT as a RT inhibitor work soon began on other drugs able to 
inhibit RT function. A second class of drugs was developed in the late 1980s and early 1990s 
called non-nucleoside RT inhibitors (NNRTI). NNRTIs inhibit RT differently than NRTIs; this 
class of drugs does not bind to the RT active site, but to a second allosteric site on RT that alters 
the enzyme’s conformation and inhibits its function. The first NNRTI approved for use in the 
United States was nevirapine in 1996. Even before the FDA approved the drug, in vitro studies 
began to show HIV’s ability to develop resistance mutations to nevirapine21. Again, HIV’s error 
prone RT results in a high number of mutant viruses, which allows for the development of a 
resistant RT molecule very quickly. 
The third major class of HIV antiretroviral drugs is protease inhibitors (PI). PIs prevent 
HIV infection by inhibiting the HIV-1 protease from cleaving viral proteins during virion 
maturation. This prevents the virion from maturing into an infective HIV particle. The first PI 
approved by the FDA was saquinavir in 1995. Similarly to the other classes of antiretrovirals, 
resistance mutations were observed in vitro before the FDA approved the drug. In 1996, after 
observing HIV’s ability to rapidly evolve resistance mutations to singular drug therapies, 
physicians began to treat HIV patients with a combination of drugs. This treatment is called 
highly active antiretroviral therapy (HAART) and consists of at least one drug from each of the 
major classes of antiretrovirals; NRTIs, NNRTIs, and PIs. The premise of this therapy is that 
using combinations of drugs makes it very difficult for HIV to simultaneously develop resistance 
mutations. The use of HAART has been very effective in keeping viral replication low and 
CD4+ T-cell counts high in chronically HIV infected individuals. While HAART has greatly 
altered the natural history of HIV infection, there are a few caveats that come with this treatment; 
HAART is very expensive, it requires very rigid adherence to maintain effective levels in the 
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blood, if therapy is stopped HIV rebounds very quickly so HAART must be continually given22, 
and there is a substantial risk of drug related side effects. 
1.1.4 Infection and Cholesterol 
A number of studies have shown that HIV infection and replication are intimately connected to 
cellular cholesterol. HIV entry occurs at sites in the cellular membrane called lipid rafts23. Lipid 
rafts are dynamic microdomains of proteins, cholesterol and sphingolipids within the cellular 
membrane. Lipid rafts are important to cell function because they bring many surface proteins 
and adaptor proteins in close proximity to each other, which enhances cellular signal 
transduction. Lipid rafts are important to a number of immune related functions, such as immune 
synapse formation and enhanced T-cell signaling by the formation of supramolecular activation 
clusters (SMACs)24. Lipid rafts are ideal sites for HIV-1 entry because they bring CD4 and 
CCR5/CXCR4 receptors in close proximity, which enhances viral attachment and fusion. HIV-1 
entry is also dependent on the presence of cholesterol that is associated with lipid rafts25. In fact, 
the treatment of cells with lovastatin, a strong inhibitor of the rate-limiting enzyme during 
cholesterol biosynthesis, inhibited HIV-1 infection at the level of virus entry26. Additionally, 
treatment of cells with oxysterol, a known suppressor of cholesterol biosynthesis by inhibition of 
SREBP2 (an important transcriptional controller of cholesterol synthesis), inhibited viral 
replication27. 
The HIV accessory protein Nef is important to viral infection and has a number of roles 
in modulated cellular functions. During assembly of new viral particles, Nef binds and transports 
cholesterol to lipid rafts present at the cellular membrane by its myristoylation. This interaction 
of Nef with cholesterol appears to be crucial in HIV infectivity28. Nef also has the ability to 
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interact with a number of cellular signaling proteins. Specifically, Nef has been shown to activate 
a number of genes involved in cholesterol biosynthesis as well as being able to decrease cellular 
cholesterol efflux28-31. There is also evidence that HIV infection has effects on cholesterol 
metabolism at a systemic level. In the absence of HAART, HIV infection itself has been 
associated with hypocholesterolemia and hypertriglyceridemia32-34. There is also evidence that 
HIV infection causes a 3- to 4-fold increase in de novo hepatic lipogenesis when compared to 
HIV negative controls35.  
1.2 DYSLIPIDEMIA 
1.2.1 Dyslipidemia, Atherosclerosis and Cardiovascular Disease Risk 
Dyslipidemia is defined as abnormal levels of lipids in the blood. This includes both increases 
(hyper-) and/or decreases (hypo-) of serum cholesterol, fats, and lipoproteins. An increased level 
of certain lipids, such as low-density lipoprotein cholesterol (LDL-C), is associated with the 
development of atherosclerosis, which is the thickening of the arterial walls throughout the body. 
Cardiovascular disease (CVD), also called coronary heart disease (CHD) or coronary artery 
disease (CAD) when refereeing to the vasculature of the heart, is the clinical manifestation of 
atherosclerosis resulting in myocardial infarction and stroke. CVD is the number one killer in the 
United States, accounting for one in three deaths among men and women in 200736. The major 
risk factors that have been associated with CHD in the general population include; blood 
pressure, cigarette smoking, total cholesterol (TCHOL), LDL-C, high-density lipoprotein (HDL-
C), lipoprotein (a), triglycerides (TRIG), diabetes, obesity and family history of CVD37-39. 
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Atherosclerosis is a complex disease process mediated largely by an inflammatory response to 
the deposition of lipids in arterial walls; because of this, certain indicators of immune function, 
e.g. C-reactive protein (CRP), have been implicated as CVD risk factors40. CVD and the risk 
factors associated with CVD vary by race and gender41-43. Dyslipidemia profiles tend to also vary 
by race and gender. Whites often have higher TRIG and lower HDL-C levels when compared to 
blacks in both men and women. Women tend to have higher TCHOL, LDL-C, and HDL-C levels 
compared to men.  
Atherosclerosis starts at sites in arterioles where laminar flow is disrupted. LDL-C 
particles enter the arterial intima and begin to elicit an inflammatory response that results in the 
recruitment of monocytes from the blood. Upon entering the intima space, monocytes 
differentiate into macrophages and begin to ingest oxidized lipid particles, taking on the 
appearance of lipid-laden foam cells. The accumulation of foam cells results in fatty streaks or 
early atherosclerotic lesions. In addition to monocytes other immune cells, e.g. T- cells, are also 
recruited to the lesion further perpetuating the local inflammation.  Over time, foam cells begin 
to undergo apoptosis releasing cellular debris and crystalline cholesterol resulting in the 
formation of a necrotic core, which further enhances the inflammatory response. At this stage the 
plaque can either stabilize preserving the luminal space or continue to grow, leading to a rupture 
of the fibrous cap and release of thrombotic material into the lumen. The thrombosis associated 
with this plaque rupture is what causes acute myocardial infarctions seen in CHD44,45. 
 Even though the risk factors associated with CVD are well established, most individuals 
diagnosed with acute coronary events were not identified as being ‘high risk’45. This observation 
has lead to the investigation of a number of clinical indicators of subclinical atherosclerosis.  
Coronary artery calcification (CAC) using computed tomography (CT) and B-mode ultrasound 
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measurement of carotid intima-media thickness (IMT) are noninvasive methods for estimating 
the plaque burden present in individuals that have not suffered acute cardiac events. These 
methods have found to be reliable independent predictors of cardiovascular disease events.  
1.2.2 HAART-Associated Dyslipidemia and Cardiovascular Disease Risk 
Infection with HIV-1 is often associated with metabolic changes that affect lipid levels, and the 
use of Highly Active Antiretroviral Therapy (HAART) can compound these effects. Despite 
their benefits in lowering plasma HIV levels, exposure to certain antiretroviral drugs can affect 
both lipid metabolism (dyslipidemia) and body fat distribution (lipodystrophy) in HIV+ 
patients46-52. These metabolic side effects, along with reports of higher cardiovascular disease 
(CVD) risk and myocardial infarction in HIV positive patients, have raised concerns of the 
potential dangers associated with HAART53-58. 
Very early on in the age of HAART use, studies began to report evidence of premature 
CAD associated with PIs57. Use of PIs is also associated with increased levels of TCHOL, LDL-
C, and TRIG along with decreased HDL-C levels46-50,59,60. A recent review61 outlined data from 
four studies comparing lipid levels in HIV-seronegative individuals exposed to PIs for short time 
periods to the levels seen in HIV-seropositive individuals receiving PI therapy62-65. These data 
showed that dyslipidemia associated with PIs is restricted to elevated TRIG levels and was seen 
only in response to one particular PI, ritonavir, in HIV-seronegative individuals. Also, when 
comparing HIV (-) to HIV (+) individuals an increased level of LDL-C was observed in the HIV 
(+) but not HIV (-) individuals after exposure to various PIs. This suggests that the increase in 
LDL-C levels associated with PI treatment in HIV (+) individuals is not due to the drug 
treatment but rather to a restoration to health. The other components of HAART – NRTIs and 
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NNRTIs – have also been associated with the development of dyslipidemia52,61. These lipid 
profiles would be considered atherogenic in the general population and may suggest an increased 
risk of atherosclerosis and CVD in patients receiving HAART. Often patients receive 
combinations of these drugs over varying periods of exposure making definitive conclusions 
about HAART-associated dyslipidemia and CVD risk very difficult. In addition, not every 
individual responds to these drugs in similar ways. For example, patients with the HLA-B*5701 
allele have a hypersensitivity to treatment with the NRTI abacavir66. We hypothesize there is a 
similar genetic susceptibility to dyslipidemia in response to HAART. 
There is evidence that HIV infection and HAART increases the risk of CVD but these 
studies often fail to correct for traditional risk factors of CVD (obesity, smoking, genetics, lipid 
levels)58,67,68. For instance, the D:A:D (Data Collection on Adverse Events of Anti-HIV Drugs) 
study initially reported a higher risk of CVD in HIV infected individuals and an association of 
antiretroviral therapy with risk of MI, but follow-up analyses revealed that this association was 
abrogated when adjusting for traditional risk factors69,70. Studies on indicators of subclinical 
coronary atherosclerosis (IMT and CAC) in HIV infected individuals have reported mixed 
results on the association of HIV infection and HAART with increased CVD risk58,71-73. 
1.2.3 Dyslipidemia and Cardiovascular Disease Genetics 
The first indication that dyslipidemia was linked to CVD, and that genetics played a role, came 
from an investigation of people who suffer from homozygous familial hypercholesterolemia. 
This inherited condition is caused by a mutation in the LDLR gene, which encodes the LDL-C 
receptor and is characterized by increased levels of serum LDL-C along with substantial 
premature atherosclerosis. The LDLR protein is located in the liver and is responsible for 
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mediating the uptake of LDL-C and very-low density lipoprotein (VLDL) from the serum into 
the liver. The mutation that causes familial hypercholesterolemia results in a defective form of 
LDLR, which can no longer effectively transport LDL-C particles from the serum into the liver. 
This association between increased serum LDL-C levels and development of atherosclerosis was 
the first of its kind and led to the understanding that modulating LDL-C levels could impact the 
development of atherosclerosis, which ultimately resulted in the use of HMG-CoA reductase 
inhibitors (statins) for use in treatment of atherosclerosis and CVD. Statins inhibit HMG-CoA 
reductase, the rate-limiting enzyme during cholesterol biosynthesis, which lowers serum LDL-C 
levels. 
CVD in the general population does not arise from just one mutation in one gene. Rather, 
CVD is a complex human disease that involves a number of metabolic processes involved in 
cholesterol metabolism and inflammation, as well as external environmental influences. Genetic 
linkage studies of inherited traits like familial hypercholesterolemia have shed light on a few of 
the processes, e.g. reverse cholesterol transport (RCT), involved in CVD but are limited in their 
scope to identifying only those genes/mutations that have a profoundly detrimental effect. 
Another way to investigate genes involved in complex human disease is to perform a genome-
wide association study (GWAS). In general, a GWAS tests for thousands to millions of single 
nucleotide polymorphisms (SNPs) that are evenly spaced across the human genome under the 
hypothesis that a common trait is associated with a common [genetic] variant. When certain 
mutations are found to be associated with a disease trait, like increased levels of LDL-C, a 
genomic region or a particular gene is identified as a potential ‘candidate’ for further 
investigation. While GWAS provide a powerful tool in investigating the genetic components to 
human disease, they do have some fundamental flaws that need to be addressed. There is a 
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potential for increased Type I errors (false positive) because of the larger number of independent 
tests being performed. To address this, a stringent statistical correction (such as Bonferroni’s 
correction) is applied or a False Discovery Rate (FDR) analysis is performed, but replication of 
positive associations across different studies remains an issue. Additionally, the SNPs identified 
by these studies often only explain a small portion of the trait variance (e.g. LDL-C levels) 
despite the large number of SNPs identified. This is either because the statistical corrections 
themselves are excessively conservative, over correcting the significance levels in an attempt to 
eliminate false positives, and/or the studies are underpowered to detect the effects of numerous 
SNPs that are individually contributing small effects of the trait of interest but collectively can 
explain a larger portion of the trait variance.  
Another concern when performing genetic association studies is population stratification. 
As populations continued to migrate out of Africa and across the globe, their genetic pools 
became increasingly more homogeneous74. As time passed, these populations of limited genetic 
information diverged from each other forming divergent groups of what we today call race or 
ethnicity. When selecting a study population consisting of many races, or ancestral populations, 
there is a potential to increase the Type I error, especially in a case-control study design75. This is 
because of the fundamental design of these types of associations and statistical procedures. Often 
allele frequencies are compared between the case and control groups under the assumption that 
people in the case group will share a common genetic variant (e.g. the allele associated with the 
disease phenotype) and have a higher frequency of this variant compared to controls. If there is 
an unequal distribution of individuals who share genetic variants due to ancestry, and not disease 
status, then this will result in a false positive association result. So, it is important to accurately 
identify what ancestral populations are present in the study population (population substructure) 
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and if possible, to keep them separate when performing association studies. This can be 
accomplished by either using self-reported race (ethnicity) or by using genetic markers that have 
very different frequencies in different ancestral populations (ancestry informative markers, 
AIMs). Self-reported race is often used to stratify populations but this may not always be 
adequate, especially when dealing with populations of mixed genetic ancestry (e.g. African 
Americans)76. 
 Over a decade of genetic association studies have investigated the genetic contributions 
to CVD and dyslipidemia with an ever-growing number of potential candidate genes and SNPs77-
97. While the numbers of candidate genes continues to expand, there are recurrent biological 
processes that have been identified as being important to dyslipidemia, atherosclerosis, and CVD 
risk. The most common of these genes are those involved in cholesterol metabolism and reverse 
cholesterol transport. This is a complex process by which cholesterol is synthesized or absorbed 
then transported to the periphery and back to the liver where it is ultimately excreted. Briefly, the 
main players in this process are the transporters of cholesterol in the blood; LDL-C which 
predominately carries cholesterol to the peripheral tissues, and HDL-C, which predominately 
transports cholesterol back from these tissues to the liver for digestion or recycling. Many of the 
candidate genes identified to date encode proteins or enzymes directly related to this transport 
mechanism, e.g. LDLR, hepatic lipase (LIPC), apolipoprotein B (APOB), cholesteryl ester 
transfer protein (CETP), and lipoprotein lipase (LPL) to name a few.  
1.2.4 Investigating the Genetic Contributions to HAART-Associated Dyslipidemia 
Dyslipidemia is common in patients receiving HAART, yet not all of these patients suffer these 
side effects. This suggests there may be an underlying genetic contribution to HAART-
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associated dyslipidemia. We hypothesized that this variation is due to the joint effect of HIV 
infection and HAART, together with the underlying genetic predisposition present in these 
individuals. To test this hypothesis we designed an Illumina GoldenGate genotyping array 
consisting of single nucleotide polymorphisms (SNPs) that had been previously associated with 
dyslipidemia and/or CVD in the general population76-86,88-90,93-95,97-108. We also included SNPs to 
provide effective coverage of the variation present in 75 candidate gene regions with similar 
associations in the general population77-87,89-91,94-96,98-109. Currently, there have been no studies 
investigating the possible differences in HAART-associated dyslipidemia by ethnicity. Since our 
study cohort is multiethnic, we included ancestry informative markers (AIMs) to accurately 
stratify our population based on genetically defined biogeographical ancestry (BGA). We used 
BGA to stratify our population because it has been shown to be superior to self-reported racial 
classifiers when investigating genetic variations associated with a disease phenotype74. 
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2.0  STUDY PREMISE 
2.1 HYPOTHESIS 
Dyslipidemia side effects are often seen in HIV-positive individuals undergoing HAART, but the 
fact that these side effects are not seen in every such individual points to a host genetic 
contribution. Many human genes are already known to affect lipid metabolism and the 
susceptibility to cardiovascular disease, and so we hypothesize that variation in human genes 
involved in lipid metabolism will contribute to the development of HAART-associated 
dyslipidemia in HIV-positive individuals. Further, as both the incidence and type of 
cardiovascular disease varies between ethnic groups in the general population, we further 
hypothesize that the ethnic groups present in the MACS may vary in their response to HAART in 
ways that influence the development of dyslipidemia. We have developed a SNP genotyping 
array to test these hypotheses in the MACS.  
2.1.1 Specific AIM #1: Population Stratification 
Define the genetic population substructure of the MACS. The MACS is a multiethnic cohort, and 
studies of similar cohorts have shown that self-reported ethnicity does not always adequately 
describe a cohort’s genetic composition. We have used a panel of Ancestry Informative Marker 
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SNPs to characterize the biogeographical ancestry of each MACS participant included in our 
study. 
2.1.2 Specific AIM #2: Dyslipidemia Present in the MACS 
Determine the extent of HAART-associated dyslipidemia in the MACS. We have determined the 
mean, pre-statin, values of the key biomarkers of dyslipidemia in the MACS, and stratified these 
by biogeographical ancestry to reveal variation between ethnic groups in their dyslipidemic 
response to HIV infection and HAART. 
2.1.3 Specific AIM #3: Genetic Associations with Dyslipidemia 
Identify key human genes that mediate the development of the dyslipidemic response to HAART 
in the MACS. We have performed both single-locus SNP and multi-locus haplotype analyses of 
MACS participants, stratified by lipid biomarkers and by biogeographical ancestry, and have 
identified specific lipid metabolism genes that significantly influence the development of 
HAART-associated dyslipidemia in the MACS. We have found that this genetic predisposition 
to the development of HAART-associated dyslipidemia varies between biogeographical ancestry 
groups in the MACS.  
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3.0  MATERIAL AND METHODS 
3.1 STUDY DESIGN 
Study participants were chosen from the Multicenter Aids Cohort Study (MACS) that had 
metabolic and lipid data recorded in the year 2005. Longitudinal data was obtained from time of 
enrollment to the last visit in 2009. The MACS is a prospective multiethnic cohort study of the 
natural history of HIV in homosexual and bisexual men in four major metropolitan areas; Los 
Angeles, CA; Chicago, IL; Baltimore, MD; and Pittsburgh, PA. Participants in the MACS are 
seen semi-annually providing us with detailed longitudinal lipid profiles from 1,945 HIV 
seropositive (n=955) and seronegative (n=950) individuals.  
3.2 PHENOTYPES AND EXPOSURES 
The mean LDL-C, HDL-C, TRIG, and TCHOL for patients were calculated according to their 
exposure group. Lipid levels used in this study were obtained solely from visits at which patients 
reported not receiving lipid-lowering medication. Three exposure groups can be defined based 
on HIV-1 infection status and highly active antiretroviral therapy (HAART) use; HIV and 
HAART negative controls (-/-), HIV positive but HAART naïve (+/-), and HIV positive 
receiving HAART (+/+). HAART use was defined in accordance with the DHHS/Kaiser Panel 
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guidelines110. For the HIV/HAART (+/-) patients (reported as not receiving HAART as of the 
last visit in 2009), the lipid phenotype values were used from visits after they had become HIV 
positive. For HIV/HAART (+/+) patients the only lipid phenotype values used were those 
obtained after the patient had been put on HAART. Only blood samples from fasting patients 
were used for the evaluation of serum lipids and the LDL-C was calculated using the Friedewald 
equation [LDL-C = TC - (HDL-C + (TRIG/5)] or by direct measurement if the TRIG level was 
above 400mg/dl. Additional covariates were obtained from CAMACS and are listed in Table 2. 
3.3 SAMPLE PROCESSING 
Peripheral blood mononuclear cell (PBMC) pellets were obtained from the MACS and genomic 
DNA was extracted using the Qiagen QIAmp DNA Blood Mini Kit using the Blood or Body 




Fluid Spin Protocol. [Qiagen Inc., Valencia, CA] The QIAmp DNA Blood Mini Kit is a silica-
gel membrane based extraction where DNA binds to the membrane while contaminants are 
eluted with successive wash steps. The extracted genomic DNA was then stored at 4°C at a total 
volume of 400 µl. To obtain the DNA quantities needed for the Illumina GoldenGate assay a 
whole genome amplification (WGA) was performed on all of the samples using the Illustra 
Genomphi V2 DNA Amplification Kit. [GE Healthcare Biosciences, Pittsburgh, PA] The 
Genomphi V2 DNA Amplification Kit yields 4-7 µg per 20 µl reaction. Extracted genomic DNA 
was first denatured at 95°C for three minutes then cooled to 4°C. The kit’s master mix, which 
contains random hexamer primers, dNTPs, and Phi29 DNA polymerase, was added and then 
incubated at 30°C for 2 hours. The WGA DNA was quantified using Quant-iT PicoGreen 
dsDNA reagent kit [Invitrogen Ltd., Paisley, Carlsbad, CA] and diluted to a concentration of 50 
ng/ml for use in the genotyping assay. PicoGreen is a sensitive fluorescent nucleic acid stain that 
binds to double-stranded DNA allowing for quantification of a wide range of DNA 
concentrations111. 
3.4 GENOTYPING AND ASSAY DESIGN 
Initially, PCR based Fluorescent Polarization (FP) was used to genotype our samples. This 
procedure only allows for the detection of one particular single nucleotide polymorphism (SNP) 
at a time. Instead we chose to use the Illumina GoldenGate technology for the genotyping of our 
samples. [Illumina Inc., San Diego, CA] This allowed us to construct a custom array of 1,536 
SNPs covering selected genes and regions of interest previously found to be associated with lipid 
metabolism and cardiovascular disease in the general population. 
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3.4.1 Fluorescent Polarization Genotyping 
Preliminary genotyping of four SNPs associated with dyslipidemia in the general population was 
performed on genomic DNA extracted from a subset of study participants. The PCR based 
Fluorescent Polarization (FP) assay was used to genotype these samples112,113. First a PCR 
reaction was performed on the genomic DNA to amplify the region around the SNP of interest. 
Then a PCR clean up (Exonuclease I/Shrimp Alkaline Phosphatase) was performed to remove 
any single stranded DNA molecules and excess primers. Following the PCR clean up a single 
base extension was performed using allele-specific dye-terminators. Two fluorophore dyes were 
used; Tamra and R110. The FP assay is based on the principle that when a fluorescent molecule 
is excited with plane-polarized light, it emits light in a fixed plane. The amount of light emitted 
and the extent at which it is polarized or depolarized is directly related to the molecular volume, 
holding temperature and viscosity of the media constant. This is due to the difference in 
molecular rotation of different sized molecules. A larger molecule will rotate and tumble less 
than a smaller molecule and thus maintain the polarization of the light emitted. The samples are 
then plotted with one dye being on the x-axis and the other on the y-axis. Samples that are 
homozygous for the SNP alleles have high FP values for one dye but not the other and 
heterozygous samples have high FP values for both dyes. Using these plots, genotype clusters 
can be defined and each samples genotype inferred. 
3.4.2 SNP Selection 
An extensive literature search was performed to identify SNPs that had been previously 
associated with dyslipidemia and/or cardiovascular disease (CVD) in the general population75-
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95,99-107. We identified 307 clinically relevant SNPs and approximately 90 genes and gene regions 
that had been associated with dyslipidemia and CVD. In the design phase, SNPs were selected 
based on the highest likelihood of success using Illumina’s design scores and validation status. 
The overall process of designing our custom array is outlined in Table 3. The list of 1,536 SNPs 




on our array can be divided into three groups; clinically relevant SNPs identified from our 
preliminary literature search, ancestry informative markers (AIMs) used for identifying 
biogeographical ancestry (BGA) and Tag SNPs that capture the allelic variation across the 
candidate genes previously identified using the linkage disequilibrium (LD) present in these 
regions.  
The process of SNP selection was similar for the clinically relevant SNPs and AIMs 
groups. Each SNP’s probe sequence (+/- 60 bps from the SNP) was first analyzed using faFrag, 
one of the Kent Source Utilities available at the University of California Santa Cruz Genome 
Browser [http://genome.ucsc.edu], which allows for the identification of polymorphic sites 
adjacent to the SNP of interest. This was important because if the patient’s sample being tested 
also had mutations at these sites the binding efficacy of the probe may be inhibited. We were 
able to annotate these SNPs in the probe sequence using degenerate nucleotide codes, which 
allowed Illumina to construct probes that accounted for the additional SNPs. After sequence 
analysis was performed the probe sequences for each SNP were submitted to Illumina’s online 
assay design tool (ADT). The ADT software uses a proprietary design algorithm to assign minor-
allele frequencies (MAF), validation status, error codes, SNP scores and designability ranks. The 
SNP score and designability rank were used as the primary quality metrics. To make sure as 
many clinically relevant and AIM SNPs were included on the array a designability rank cutoff of 
≥0.5 was used for these probes. The Illumina designability rank is a number ranging from 0 to 1 
that summarizes the estimated viability of an assay. Illumina also uses a rank score of 1.1 to 
denote assays that have previously been validated as successful. Due to the length of the primers 
used in the Illumina GoldenGate assay, no SNP on the array could be within 60 bps of another 
 28 
SNP included on the array. We used an iterative process of adding and removing SNPs based on 
this 60 bp criteria to maximize the number of SNPs included on the array. 
A different selection process was used for the Tag SNP group. After identifying the 
candidate gene regions from the literature search, a list of 90 genes was submitted to the Illumina 
ADT software. Each candidate gene region was defined to include 10kb upstream and 
downstream of the 5’ and 3’ UTRs, respectively. The 10kb extension allows us to test the 
variation present in the promoter and other regulatory regions adjacent to the candidate gene. 
(Table 4) The ADT software, using human Genome Build 36 and dbSNP Version 126, returned a 
list of over 50k Illumina SNPs known and validated in these gene regions. The general selection 
scheme is outlined in Table 3. These SNPs were then used as a reference panel to create a set of 
Tagging SNPs for each candidate gene region using the Tagger algorithm in Haploview114. Only 
SNPs from the Illumina list that had a designability rank = 1.0 were used in the reference panel. 
The selection of Tag SNPs based on the LD present in each gene allows us to genotype a 
minimal number of SNPs and still provides information about a larger number of nearby variants 
that were not genotyped. The tagging strategy was as follows: Haploview was set to version [2], 
release [22], and analytical panel CEU (Utah residents with ancestry from northern and western 
Europe); a pair-wise r2 ≥ 0.8 was used to identify the Tag SNPs and a minimum distance of 60 
bps was set between each SNP. Even though the MACS is a multi-ethnic cohort we chose to use 
the HapMap CEU reference population to design the Tag SNP panel because the LD structure is 
better defined in the CEU population compared to the other admixed populations, e.g. the ASW 
(African ancestry in southwest USA) HapMap population, and the majority of our samples were 
predicted to be primarily of European ancestry similar to the CEU reference population. A pair-
wise r2 threshold of ≥ 0.8 was used because it gives the minimum number of tags required while  
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Table 4 - Gene List 
maintaining almost complete power relative to that of the reference panel115. After the lists of 
Tag SNPs for each gene were generated the sequences were analyzed using faFrag as described 
above. Any additional mutations in the +/- 60 bp window around the SNP were replaced with the 
degenerate nucleotide code and resubmitted to the ADT software for validation. The Tag SNPs 
were then checked for error codes, SNP scores and designability ranks. SNPs whose 
designability rank had dropped below 1.0 were removed and the Tagger algorithm was rerun to 
adjust for the loss of these SNPs. The sequence analysis was repeated and the SNP list was 
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resubmitted to ADT. The primary goal during this process was to maximize the allelic coverage 
of each gene region by using the minimum number of SNPs with the highest likelihood of 
success on the GoldenGate array. 
All three SNP groups were combined to complete the final 1,536 SNP panel and then 
were submitted to Illumina’s ADT for validation. If there were any further errors identified by 
the ADT software the processes for each SNP group, reviewed above, were repeated. Mainly this 
consisted of re-Tagging certain gene regions to account for the addition of the clinically relevant 
SNPs. In some cases we were able to identify additional ‘tag’ SNPs in high LD with some of the 
clinically relevant SNPs that were unable to be included on the array.  
3.4.3 GoldenGate Genotyping 
The Illumina GoldenGate Assay was used to genotype 1,914 samples from the MACS. The 
GoldenGate technology allows for the design of a custom panel of 1,536 SNPs. WGA DNA 
samples were submitted to the Genomics and Proteomics Core Laboratories (GPCL) at the 
University of Pittsburgh in 96 well plates. Each plate contained 4 randomly selected known 
samples for replicate analysis and 4 population controls consisting of one family of both parents 
and two children, used to control for Mendelian consistency of the genotype data. 
 The first step in the Illumina assay is to activate the genomic DNA for binding to 
paramagnetic particles. The next step involves the primer hybridization of the assay 
oligonucleotides to the genomic DNA bound to these particles. Illumina designs three 
oligonucleotides for each SNP. Two allele-specific oligos (ASO) bind directly upstream of the 
SNP and one locus-specific oligo (LSO) that binds farther downstream of the SNP. Following 
the hybridization step a product is formed that contains a single ASO and a LSO; this acts as the 
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template for the next step in the assay. A PCR reaction is performed on this template, where dye-
labeled primers specific to the ASO are added to the reaction. The PCR product contains allele-
specific dyes to the SNP and a unique address sequence produced from the LSO. The address 
sequence targets the single stranded product to the bead specific to that SNP located on the array. 
The single-stranded dye-labeled DNAs hybridize to their complement bead located on the array 
matrix. We received raw fluorescent data files and raw image files that were analyzed using the 
Illumina BeadStudio software package. Genotypes were called using the standard clustering 
algorithm in BeadStudio. Each SNP's cluster graph was examined individually and genotype 
calls were adjusted according to visual inspection. 
3.5 QUALITY CONTROL 
3.5.1 Samples 
Samples were excluded if the replication error rate of the repeated samples was > 10% or if the 
sample call rate was < 90%. We also used the 10% GenCall (GC) score, which is the 10th 
percentile of GC scores in the given distribution of sample GC scores. The GC score is a 
proprietary Illumina quality control metric that ranges from 0 to 1. GenCall scores are calculated 
for each genotype and generally decrease the further a sample is from the center of cluster it is 
associated with. Illumina suggests an initial GC cut-off of 0.15; we used a cut-off of 0.25 to 
screen our genotypes. Through graphical examination we excluded any samples below a 
threshold of 0.40 10% GC because samples below this threshold were associated with low 
sample call rates and were identified as low quality samples. (Figure 4A) Manual examination of 
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sample graphs was also performed in the BeadStudio with samples having abnormal distributions 
being excluded. These abnormal distributions were the result of improper hybridization and the 
samples were repeated. 
 
Figure 4 - GenCall Distributions 
(A) 10% GC scores for each sample tested on the GoldenGate array. Index represents the ordered sample 
10% GC scores. (B) 50% GC scores for each SNP tested on the GoldenGate array. Index represents the 
ordered SNP 50% GC scores.   
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3.5.2 SNPs 
Loci were excluded if the minor allele frequency (MAF) was < 0.01 in our data set and if the 
locus call rate was < 80%. When performing the association analysis a MAF of 0.05 was used as 
a cutoff and was specific to the subpopulation being tested. We used the BeadStudio quality 
metric 50% GC, 50th percentile of locus GC scores, to exclude loci with a score < 0.50 by 
graphical examination. (Figure 4B) Manual examination of SNP graphs was performed in 
BeadStudio and loci exhibiting evidence of copy number variation (CNV), having more than 
three distinct cluster or abnormal clustering, were removed. Figure 5 shows examples of SNP 
genotype graphs that shows evidence of possible CNV (A) compared to a SNP that shows good 
genotype clustering (B). 
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Figure 5 - Example SNP Clustering Plots 
3.6 GENETIC ANALYSIS 
3.6.1 Population Stratification 
Using the 113 AIMs that passed our QC process we performed a multidimensional scaling 
(MDS) procedure to cluster individuals based on pairwise identity-by-state (IBS) distances. This 
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was done using the Multidimensional Scaling Population Stratification (MDS) procedure in 
PLINK116. We included reference populations downloaded from the HapMap database to 
identify the biogeographical ancestral origin of each cluster in our population. (Figure 6) In order 
to define clear boundaries between the biogeographical ancestral clusters, we performed a k-
means clustering algorithm on the first two components of the MDS procedure. We specified 3 
possible cluster positions in the k-means procedure. We used these cluster positions to define 
two main groups, European ancestry (EA) and African/European ancestry (AEA), which were 
used for our analyses. The k-means procedure was performed in the R software package117. 
3.6.2 Quantitative Trait Loci (QTL) Analysis 
For single locus association the mean lipid phenotypes were regressed on each SNP using 
multivariate linear regression. Each SNP was tested using dummy variables (0,1,2) that 
represented the dosage of the minor allele assuming an additive genetic model. The first two 
components of the MDS procedure were included as covariates to control for population 
stratification. For the multi locus association tests haplotypes were constructed in PLINK using 
the haplotype blocks estimation procedure, which is based on pairwise linkage disequilibrium 
(LD). We then used these haplotypes in a linear regression test for association with mean lipid 
levels using the Haplotype-Based Association Test with the GLM procedure in PLINK. 
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Figure 6 - HapMap Reference Population Clustering 
Biogeographical ancestry in the MACS compared to HapMap reference populations. Scatter plot of the 
first two components from the MDS on the combined MACS and HapMap samples. Colors represent 
individuals from MACS or HapMap reference populations. Individuals from the MACS study are shown 
in grey. Individuals taken from the HapMap: African ancestry in the southwest USA (ASE) are shown in 
orange; Utah residents with Northern and Western European ancestry (CEU) from the CEPH collection 
are shown in blue; Chinese in metropolitan Denver, Colorado (CHD) are shown in light green; Mexican 
ancestry in Los Angles, California (MEX) are shown in dark green; and Yoruba (YRI) in Ibadan, Nigeria 
are shown in red 
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3.7 STATISTICAL ANALYSIS 
Empirical p-values were calculated using both adaptive (aPerm) and max(T) (mPerm) 
permutation procedures in PLINK. Empirical p-values were calculated using 1x106 permutations 
for the single locus association and 1x104 permutations for the haplotype based association. 
Briefly, the aPerm is a test of each SNP’s asymptotic p-value against the permutated p-value 
distribution. The mPerm is a test of each SNP’s asymptotic p-value against the distribution of the 
maximum permutated p-values from each permutation. The Bonferroni correction for multiple 
independent tests was performed using PLINK. The genomic inflation factor was obtained from 
the standard PLINK output when running association tests. QQ-plots of each association’s p-
values were calculated and plotted in R. 
Mean Lipid Phenotype = β1s + β2c1 + β3c2 + β4h + β5s*h 
Each SNP, s, was tested with the first two components of the MDS, c1 + c2, to control 
for population stratification. The patient’s exposure group is represented by h, and the interaction 
between each SNP and exposure group is represented by the final term s*h. This term tests if 
there is an interaction of HIV infection plus HAART treatment on each SNP's effect on mean 
lipid levels compared to the HIV/HAART (-/-) group. Classical covariates associated with lipid 
levels and CVD were not included in our model because it has been shown that a reduced model 
is best suited to detect genetic effects118. Analysis of Variance (ANOVA) was performed on 
mean lipid levels by biogeographical ancestry and HIV/HAART status, including an interaction 
term for BGA and HIV/HAART. This was performed using the [aov] procedure in R. Pairwise 
comparison of the means for all groups was carried out using the Tukey’s Honest Significant 
Difference (TukeyHSD) procedure in R. The TukeyHSD test was used because it is a single-step 
procedure that compares all possible pairwise comparisons and controls for these multiple-
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comparisons. It also works well in conjunction with the ANOVA model and handles unequal 
samples sizes better than some other statistical tests. It should be noted that the sample sizes for 




4.0  RESULTS 
4.1 PRELIMINARY GENOTYPE DATA AND QUALITY CONTROL 
4.1.1 Preliminary Genotyping Using Fluorescence Polarization 
Initially we had intended to use FP as the primary genotyping methodology for our study. As 
genomic DNA was extracted from the PBMC cell pellets we performed FP genotyping on a 
subset of samples for a small number of polymorphisms that had previously been shown to be 
associated with RCT91. The summary of the genotype and allele frequencies obtained from these 
experiments is shown in Table 5. Genotypes were called by plotting the degree of polarization 
(mP value) for the dyes against each other and defining clusters of sample that had high mP 
values for one or both of the dyes. (Figure 7) These experiments showed we could successfully 
extract genomic DNA from the PBMC cell pellets and that these DNAs were viable for PCR 
based genotyping.  
 Using FP is a cost effective and efficient methodology when investigating a limited 
number of SNPs in a small number of individuals. Our initial hypothesis focused on the possible 
genetic susceptibilities to HAART-associated dyslipidemia present in genes related to RCT 
based on the work of Morabia et al., which associated polymorphisms in 11 genes involved in 
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RCT with extreme serum lipid levels91. Even though it has been shown that polymorphisms in 
 
Figure 7 - Genotype Clustering (FP) rs2294313 
RCT genes play an important role in determining serum lipid levels, there remains a large 
number of genes associated with dyslipidemia and CVD that we were unable to investigate 
efficiently using FP genotyping. Given; there are approximately 80-100 genes that have been 
associated with dyslipidemia and CVD, our sample population of 1,945 individuals, and our 
ability to produce 1,000 genotypes a week using FP, it would have taken just over 57 years to 
effectively test all the known SNPs and genes associated with serum lipids and CVD. 
Fortunately, technology exists that can test thousands to millions of SNPs at the same time on a 
large number of samples. For further genotyping and association studies, we transitioned our 
 41 
study to a high-throughput genotyping platform utilizing a custom designed Illumina 
GoldenGate genotyping assay. 
Table 5 - Fluorescent Polarization Genotyping Summary 
 
4.1.2 Quality Control 
From the total 1,945 samples, 1,914 passed our quality control (QC) filters, described in 
methods, yielding an overall sample success rate of 98% with a mean sample call rate of 95%. 
All of the 108 replicate samples displaying proper hybridization had duplicate concordance rates 
of >90%. A total of 1,281 loci passed our QC filters giving an overall locus success rate of 83% 
with a mean locus call rate of 99%. Specifically, 214 of the 267 clinical SNPs (80%), 954 of the 
1,145 tag SNPs (83%) and 113 of the 124 AIMs (91%) passed QC procedures. In order to 
maximize the number of previously published clinically relevant SNPs present on our array we 
accepted lower designability rank during the design stage, accepting a score as low as 0.5 in 
some cases for these probes. This leniency accounts for the higher failure rate in the clinical SNP 
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group. Because of our diligence during the GoldenGate design phase, we have achieved a high 
rate of success for the loci being tested and produced a high quality set of data from which to 
perform the genetic association studies. 
4.2 POPULATION STRATIFICATION 
Population stratification introduces bias in genetic association studies increasing the probability 
of both Type I and Type II errors119. The MACS is a multi-ethnic cohort study, thus the 
population substructure is important to define before we conduct our analyses. We included 124 
ancestral informative markers (AIMs) in our array to aid us in defining the ancestral populations 
present in the MACS. These are SNPs that have been shown to provide an accurate stratification 
of the component biogeographical ancestral source groups in an admixed population120. After 
genotyping our samples 113 AIMs passed our quality control metrics and were used in the 
substructure analysis.  Pairwise identity-by-state (IBS) distances for the 1,914 samples that 
successfully genotyped were calculated using these AIMs. Then multi-dimensional scaling 
analysis (MDS) was performed using the IBS distances.  
 We first looked at the population structure using self-reported race categories which was 
suggested by Driver et al.,76. The study enrollment questionnaire used by the MACS has eight 
possible racial categories: White-non-Hispanic, White-Hispanic, Black-non-Hispanic, Black-
Hispanic, American Indian or Alaskan Native, Asian or Pacific Islander, Other, and Other-
Hispanic. We restricted our analysis to the two largest groups, the White-non-Hispanic (n=1,260) 
and the Black-non-Hispanic (n=485), which together account for 1,745 of the 1,945 samples 
originally studied. We stratified the self-reported racial groups into three subgroups to simplify 
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the visualization: White-non-Hispanic (WnH); Black-non-Hispanic (BnH); and Other (Oth), 
accounting for a further 200 individuals in all. The first two components of the MDS are shown 
in Figure 8A and show good stratification of our population with what appears to be three 
primary ancestral clusters. To clarify the ancestral population composition of each cluster we 
used the genotype data that are available for these AIMs in five reference populations from the 
HapMap database (Figure 6). Using these reference populations we confirmed the WnH cluster 
as co-clustering primarily with individuals of European descent, the BnH cluster as co-clustering 
with individuals of mixed Sub-Saharan African and European descent, and the Oth cluster as co-
clustering with individuals of mixed European and Asian descent. A number of individuals give 
a self-reported race that does not agree with their biogeographical ancestry (Table 6) and this 
misclassification is a potential problem in our association studies. To resolve this, we performed 
a K-means clustering procedure on the first two components of the MDS. This allowed us to 
define three biogeographical ancestral groups based on their genetic relatedness. The results 
from these procedures are shown in Figure 8B and summarized in Table 6. We will use these 
genetically defined biogeographical ancestral groups for all our following analyses, focusing on 
individuals of European (EA) and African/European (AEA) descent. 
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Figure 8 - Population Substructure in the MACS 
Population sub-structure in the MACS. (A) Scatter plot of the first two components from the MDS procedure 
with dots representing individuals from the MACS. Colors represent self-reported race (SRR). Individuals 
who self-report as Black-non-Hispanic (BnH) are shown in red, individuals who self-report as White-non-
Hispanic (WnH) are shown in blue and individuals who self-report as one of the White-Hispanic, Black-
Hispanic, American Indian or Alaskan Native, Asian or Pacific Islander, Other, or Other-Hispanic (Oth) are 
shown in green. (B) Scatter plot of the first two components from the MDS procedure with dots representing 
individuals in our study population from the MACS. Here, colors represent defined biogeographical ancestry 
(BGA) after k-means clustering analysis was performed on the first two components of the MDS. Individuals 
with an ancestry derived from populations of African and European descent (AEA) are shown in red. 
Individuals with primarily European ancestry (EA) are shown in blue, and individuals with a complex 
ancestry derived from Asian and European descent (AsEA) are shown in green. 
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Table 6 - MACS Demographic Data 
 
4.3 SERUM LIPIDS IN HIV/HAART PATIENTS DIFFER BY BIOGEOGRAPHICAL 
ANCESTRY 
To assess the extent of dyslipidemia in our cohort we investigated four serum lipid phenotypes: 
TCHOL, LDL-C, HDL-C, and TRIG. We were able to use longitudinal lipid phenotype data 
obtained for every individual enrolled in our study to define a physiological baseline for use in 
our genetic association studies. To do this, we took means of every individual’s visit excluding 
those at which patients reported taking cholesterol-lowering medications, such as statins. Using 
the mean value from multiple visits for a particular analyte has been shown to be accurate and in 
some cases superior to a single measurement121. We will refer to these mean lipid levels 
throughout the paper as mTCHOL, mLDL-C, mHDL-C, and mTRIG. 
Three possible treatment groups are present in each biogeographical ancestral population: 
HIV negative / HAART negative controls (-/-), HIV positive / HAART naïve individuals (+/-), 
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and HIV positive patients receiving HAART (+/+). The means of each group were calculated 
 
Figure 9 - Mean Serum Lipids Vary by Biogeographical Ancestry and HIV/HAART Status 
Mean serum lipids vary by biogeographical ancestry (BGA) and HIV/HAART status. (A) Mean 
mTCHOL by HIV/HAART status. (B) Mean mLDL-C by HIV/HAART status. (C) Mean mHDL-C by 
HIV/HAART status. (D) Mean mTRIG by HIV/HAART status. The means of the European ancestral 
(EA) group are shown in blue and the means of the African/European ancestral group (AEA) are shown 
in red. Bars indicate standard error of the mean. Asterisks denote a significant pairwise comparison 
(TukeyHSD) of the mean serum lipid level of HIV/HAART (+/+) to HIV/HAART (-/-) within an 
ancestral group. [** = < 5.00 x10-4, *** = < 5.00 x10-7] 
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and plotted by HIV/HAART status and biogeographical ancestry (Figure 9). We performed an 
ANOVA as a formal test of the effects of biogeographical ancestry and HIV/HAART status. 
Additionally pair-wise comparisons of groups were performed using Tukey’s Honest Significant 
Difference test (TukeyHSD). (Table 7) We have indicated the p-values for the comparison of 
HIV/HAART (+/+) to HIV/HAART (-/-) groups in Table 7, but all possible pair-wise 
comparisons were performed. We have concentrated our analysis on the HIV/HAART (-/-) and 
(+/+) groups for two reasons. Firstly, the HIV positive yet HAART naïve group is composed of a 
small number of individuals in comparison to the (-/-) and (+/+) groups, and secondly because 
they represent a unique population. They are either very recently infected with HIV, or have 
genetic features that allow for the control of HIV infection, and these features themselves may 
influence their dyslipidemic response to HIV infection.  
Table 7 - Lipid Phenotypes by Biogeographical Ancestry and HIV/HAART Status 
 
The mean mTCHOL levels for each ancestral group appear to vary similarly between the 
groups, with no significant difference between the HIV/HAART (-/-) and (+/+) groups seen for 
either population (Figure 9A). Biogeographical ancestry (P = <2.20x10-16) and HIV/HAART 
status (P = 3.62x10-5) had significant effects on mTCHOL but the interaction of the two (P = 
0.072) was not significant and the pair-wise comparisons of HIV/HAART (+/+) to (-/-) controls 
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were not significant for both ancestral groups (AEA P = 0.08 | EA P = 0.98). (Table 7) This 
indicates that while HIV infection and HAART treatment appears to have an affect on mTCHOL 
levels, it doesn’t appear to alter significantly the mean level in HIV/HAART (+/+) patients when 
compared to (-/-) controls.  
Although no significant differences are seen in overall cholesterol levels, closer 
inspection of cholesterol subtypes does reveal some significant differences between ancestral 
groups and between HIV/HAART status groups. For example, mean mLDL-C levels vary 
differently between HIV/HAART status groups depending on genetic ancestry. (Figure 9B) The 
results of the ANOVA analysis show that HIV/HAART status (P = 1.18x10-12) and 
biogeographical ancestry (P = 1.45x10-13) have significant effects on the mean mLDL-C level. 
Additionally there is a significant interaction between HIV/HAART status and biogeographical 
ancestry (Table 7). The mean mLDL-C levels in the EA population are similar in the 
HIV/HAART (-/-) and (+/-) groups but are significantly lower in the (+/+) group. This lower 
mean mLDL-C level in the EA HIV/HAART (+/+) group is highly significant (P = 1.96x10-4) 
when compared to the (-/-) men. The mean mLDL-C level in the AEA population is much lower 
in the HIV/HAART (+/-) group than in the (-/-) control group. The mLDL-C level in the AEA 
HIV/HAART (+/+) group is significantly lower than in the (-/-) group (P = 1.85 x10-4). These 
results show that, for both ancestral populations, the mean mLDL-C level is much lower in HIV 
positive men receiving HAART when compared to HIV/HAART negative controls.  
The mean mHDL-C levels for both ancestral populations are lower in the HIV/HAART 
(+/-) group when compared with their (-/-) controls. (Figure 9C) The mean mHDL-C level in the 
AEA HIV/HAART (+/+) population was not significantly different in comparison to AEA (-/-) 
controls. In contrast, the mHDL-C level in the EA population was significantly lower in 
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HIV/HAART (+/+) patients than in (-/-) controls (P < 1.00x10-7). (Table 7) The ANOVA results 
show that HIV/HAART status (P = 3.96x10-15) and biogeographical ancestry (P = 1.88x10-7) 
have significant effects on mHDL-C levels. The interaction between the two is not significant 
with a p-value of 0.059. These results show that the mean mHDL-C levels don’t significantly 
differ for men of mixed African and European ancestry when infected with HIV and receiving 
HAART. Yet, for individuals of European ancestry the mean mHDL-C level of HIV/HAART 
(+/+) men is significantly lower when compared to the (-/-) controls, indicating that the impact of 
HIV infection and HAART use on mHDL-C levels differs between ancestral groups. 
The mean mTRIG levels for both ancestral populations seem to be similar for 
HIV/HAART (+/-) men in comparison with (-/-) controls. In the EA population the mean 
mTRIG levels are almost 2-fold higher in the HIV/HAART (+/+) men (P < 0.00x10-6) when 
compared to the (-/-) controls. (Figure 9D) In the AEA population the mean mTRIG levels 
appear to be slightly higher in the HIV/HAART (+/+) group in comparison with the 
HIV/HAART (-/-) controls but this difference is not statistically significant (P = 0.08). The 
results of the ANOVA show that the mean mTRIG levels are significantly affected by both 
biogeographical ancestry (P = 2.16x10-7) and HIV/HAART status (P = 2.20x10-16). There is 
evidence of an interaction between these two factors (P = 7.00x10-3) and their effect on mean 
mTRIG levels. These results show that HIV infection and HAART do not seem to have 
significant affects on the mean mTRIG levels in men of mixed African and European ancestry, 
but that there appears to be a substantial effect of HIV infection and HAART therapy on the 
mean mTRIG levels in men of primarily European ancestry. 
 Our results show an important contribution of biogeographical ancestry on dyslipidemia 
beyond the known effects of HIV and HAART. The dyslipidemia profile in HIV/HAART (+/+) 
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individuals of primarily European ancestry is characterized by lower mLDL-C and mHDL-C 
levels, higher mTRIG levels but by no difference in mTCHOL. The lipid profile in HIV/HAART 
(+/+) men of mixed African and European ancestry is different, characterized by lower mLDL-C 
but no statistically significant changes in the other three lipid phenotypes. 
4.4 GENETIC ASSOCIATIONS WITH SERUM LIPIDS 
4.4.1 Single Locus Associations in HIV/HAART (+/+) 
The results of the single locus association tests for lipid phenotype in HIV/HAART (+/+) men 
are shown in Figure 10.  Each SNP was regressed against the mean lipid phenotype using 
multivariate linear regression and an additive genetic model with the first two components from 
the MDS included as covariates to control for any residual population stratification. Details of 
each association, including the number of individuals tested, genomic inflation factor and QQ-
plots are shown in Figure 11 and summarized in Table 8. The QQ-plots show marked departure 
from an ordered normal distribution of p-values under the null hypothesis, most noticeable in 
(Figure 11-E) the QQ-plot for mHDL-C in the European ancestral group. This departure is most 
likely due our candidate gene study design, where we expect to have an enrichment of SNPs with 
positive associated p-values because we selected loci based on previous positive associations 
with serum lipid levels in the general population. Surprisingly there seems to be a substantial 
genomic inflation present in our study (Table 8) even though we went to great lengths to control 
for population substructure, the usual suspect when observing such high genomic inflation 
factors. The genomic inflation is most markedly increased in the association tests performed on  
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Figure 10 - Association Results for Serum Lipids in HIV/HAART (+/+) Patients 
Results from the genetic association with the serum lipid phenotypes by ancestral population in 
HIV/HAART (+/+). (A) Manhattan plot of the –log10 association p-values by genomic position in the 
European ancestral group. (B) Manhattan plot of –log10 association p-values by genomic position in the 
African and European ancestral group. Association results from four serum lipid phenotypes are shown; 
red = mHDL, tan = mLDL, light blue = mTCHOL, and dark blue = mTRIG. The grey horizontal line 
represents a p-value of 0.05, blue horizontal lines represent a genomic significant p-value corrected for 




Figure 11 - QQ-Plots of HIV/HAART (+/+) Association P-values 
Quantile-Quantile plots from the single locus genetic association studies. QQ-plots of expected vs. 
observed p-values from the genetic association with: mTCHOL (A, B); mLDL-C (C, D); mHDL-C (E, F); 
and mTRIG (G, H) in European (EA) and African/European ancestral (AEA) populations. The blue lines 
represent a line with a slope of one and an intercept of zero. 
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Table 8 - Association Diagnostics (+/+) 
 
the population of predominately European ancestry, even though this population should be the 
most ancestrally homogeneous of the two we tested. Taken together the residual deviations of the 
QQ-plots and the large inflation factors may be suggesting undefined familial relationships, 
unknown sample duplications, or poorly calibrated test statistics. We do not feel these results are 
indicative of a systematic bias in our data as is usually introduced by uncontrolled populations 
stratification but rather these results are reflecting characteristics of p-values that might be 
expected when performing a candidate gene association study. 
 In the European population 1,050 SNPs were tested and four loci (rs1532624, rs1532625, 
rs711752, and rs708272) had significant effects on mHDL-C levels at a Bonferroni-corrected 
critical p-value of 4.77x10-5 with unadjusted p-values of 1.66x10-5, 2.36x10-5, 4.48x10-5, and 
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4.59x10-5 respectively. All four SNPs are located in the cholesteryl ester-transfer protein (CETP) 
gene region on chromosome 16 (Figure 12-A). In the African/European population 1,071 SNPs 
were tested and two loci, rs261334 (P = 6.53x10-6) and rs4783961 (P = 9.83x10-6), had 
significant effects at the Bonferroni-corrected critical p-value of 4.66x10-5 respectively on 
mLDL-C and mHDL-C levels. The rs261334 SNP is located in the hepatic lipase (LIPC) gene 
region on chromosome 15 (Figure 13) and rs4783961 is located in the CETP gene region on 
chromosome 16 (Figure 12-B), but is not one of the SNPs in CETP shown above to affect 
mHDL-C levels in the European population. We also tested for the possible interaction of 
HAART with each lipid phenotype by adding an interaction term to our model and testing the 
control population HIV/HAART (-/-) and (+/+) groups. This interaction term tests for a 
difference in association with a phenotype between two groups and can suggest a gene X 
environment (HIV/HAART) interaction (Table 9). Of the six positive loci associated with lipid 
phenotypes, two showed significant differences in effect compared to the control population, 
rs261334 (Pinter = 9.92x10-7) and rs4783961 (Pinter = 6.78x10-4). Taken together these results 
show that polymorphisms in the LIPC and CETP gene regions that are associated with serum 
mLDL-C and mHDL-C cholesterol respectively in HIV positive men receiving HAART. 
Importantly, these associations seem to differ by biogeographical ancestry and may be affecting 
these serum lipids in ways different than in HIV negative HAART naïve individuals. 
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Figure 12 - Association Results for mHDL-C in the CETP Gene Region 
Positive association results for mHDL-C in the CETP gene region on chromosome 16 for HIV/HAART 
(+/+). (Top) Genomic position (bp) of each SNP tested in the CETP gene region on chromosome 16. 
(Middle) The –log10 p-values with arrows indicated direction of effect of each SNP and red lines 
indicated genomic significance (AEA = 4.66x10-5, EA = 4.77x10-5), beta is the coefficient from each 
SNP’s multiple linear regression equation and represents effective size, and CAF or coding allele 
frequency is the minor allele frequency of each SNP. (Bottom) Linkage disequilibrium plots generated 
from our genotype data for each ancestral group; (A) Association results in the European ancestral group. 




Figure 13 - Association Results for mLDL-C in the LIPC Gene Region 
Association results for mLDL-C in the LIPC gene region on chromosome 15 for HIV/HAART (+/+). 
(Top) Genomic position (bp) of each SNP tested in the LIPC gene region on chromosome 15. (Middle) 
Red indicates AEA population and blue is the EA population. The –log10 p-values with arrows indicated 
direction of effect of each SNP and the red horizontal line indicates genomic significance at 4.66 x10-5. 
Beta represents is the coefficient from each SNP’s multiple linear regression equation and indicates 
effective size, and CAF or coding allele frequency is the minor allele frequency of each SNP. (Bottom) 
Linkage disequilibrium plot across the LIPC gene region calculated using genotype data from the 
African/European population. Plot was generated in Synthesis-View122. 
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Table 9 - Results from Genetic Association Studies HIV/HAART (+/+) 
 
4.4.2 Multilocus Haplotype Associations in HIV/HAART (+/+) 
We next tested for haplotypes that may be associated with serum lipid levels in our populations 
by constructing haplotypes specific to each biogeographical ancestral population on the basis of 
the LD structure present in our genotype data. In the European population, 1,050 Tag SNPs were 
used to construct haplotypes in 230 genomic regions based on LD, which produced 875 discrete 
haplotypes that were then used for analysis. In the African/European population 1,071 Tag SNPs 
were used to construct haplotypes in 224 genomic regions yielding 798 discrete haplotypes. Two 
haplotypes were associated with mHDL-C in HIV/HAART (+/+) at the Bonferroni corrected p-
value of 5.71x10-5 in the European ancestral group (Table 9). Both haplotypes are independent 
three SNP haplotypes located in the CETP gene region on chromosome 16.  The most significant 
is an AAA haplotype for the three SNPs [rs11076174, rs1532625, and rs1532624 | P = 2.36x10-5] 
spanning a 2.3Kb region of the CETP gene. The SNPs in this haplotype are all located in intronic 
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regions of CETP and span over five coding regions. The second is an AAA haplotype consisting 
of three SNPs [rs711752, rs708272, and rs820299 | P = 4.77x10-5] spanning a 4.1Kb region 
located 2.9Kb from the other significant haplotype in the CETP gene, but with no LD between 
these haplotypes. Similarly to the previous haplotype, these SNPs are located in intronic regions 
of CETP but this haplotype spans a region in the first intron that has been shown to possess a 
number of histone modification sites, or marks. These histone marks are often associated with 
epigenetic modifications that modulate the transcriptional activity of the gene. There were no 
haplotypes from the African/European ancestral group with significant p-values at the 
Bonferroni corrected critical limit. These results show two haplotypes located in the CETP gene 
that have significant effects on serum mHDL-C cholesterol levels in HIV positive patients 
receiving HAART of European ancestry, identifying this gene as critically important in the 
development of the HAART-associated dyslipidemia phenotype in this population. 
4.4.3 Single Locus Associations in HIV/HAART (-/-) Controls 
Lastly, we tested for genetic associations with serum lipid levels in the HIV/HAART (-/-) control 
population. The results from the single locus associations are shown in Figure 14. 14-A shows 
the association results in the European ancestral group. A total of 1,054 SNPs were tested in this 
population with a total of 8 SNPs being statistically significant at a Bonferroni-corrected critical 
p-value of 4.74x10-5. Four SNPs; rs3764261, rs173539, rs11076175, and rs711752 were 
associated with serum mHDL-C levels with unadjusted p-values of 1.52x10-6, 2.05x10-6, 
4.13x10-6 and 3.96x10-5 respectively (Table 10). All four of these SNPs are located in the CETP 
gene region on chromosome 16 (Figure 15). The remaining four SNPs; rs2072560, rs964184, 
rs662799, and rs9326246 were associated with mTRIG levels having unadjusted p-values of 
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2.36x10-6, 3.5x10-6, 4.64x10-6, and 6.07x10-6 respectively. These four SNPs are located in the 
BUD13 homolog (BUD13) / zinc finger protein 259 (ZNF259) / apolipoprotein A-V (APOA5) 
gene region on chromosome 11 (Figure 15). Presumably, these SNPs are reflecting variations in 
the APOA5 gene, which plays an important role in plasma TRIG levels, but these genes are 
located too closely together to definitively rule out the role of the other two. The 
African/European ancestral group had no genomically significant associations with any of the 
serum lipid phenotypes we tested. (Figure 14-B) These results show that SNPs in CETP and 
BUD13/ZNF259/APOA5 gene regions are associated with serum mHDL-C and mTRIG levels, 
respectively, in HIV negative HAART naïve men of European Ancestry. In contrast, there were 
no associations with serum lipid levels in the HIV negative HAART naïve men of mixed African 
and European ancestry. 
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Figure 14 - Association Results for Serum Lipids in HIV/HAART (-/-) 
Results from the genetic association with the serum lipid phenotypes by ancestral population in 
HIV/HAART (-/-). (A) Manhattan plot of the –log10 association p-values by genomic position in the 
European ancestral group. (B) Manhattan plot of –log10 association p-values by genomic position in the 
African and European ancestral group. Association results from four serum lipid phenotypes are shown; 
red = mHDL-C, tan = mLDL-C, light blue = mTCHOL, and dark blue = mTRIG. The grey horizontal line 
represents a p-value of 0.05, blue horizontal lines represent a genomic significant p-value corrected for 




Figure 15 - Associated Gene Regions in HIV/HAART (-/-) Patients of European Ancestry 
Positive association results for HIV/HAART (-/-) of European ancestry (Top) Genomic position (bp) of 
each SNP tested in the CETP gene region on chromosome 16. (Middle) The –log10 p-values with arrows 
indicated direction of effect of each SNP and the red line indicated genomic significance (EA = 4.77x10-
5), beta is the coefficient from each SNP’s multiple linear regression equation and represents effective 
size, and CAF or coding allele frequency is the minor allele frequency of each SNP. (Bottom) Linkage 
disequilibrium plots generated from our genotype data; (A) Association results with serum mHDL-C 
levels in the CETP gene region on chromosome 16 for the European ancestral group. (B) Association 
results with serum mTRIG levels on chromosome 11 for the European ancestral group. Plots were 
generated in Synthesis-View122 
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Table 10 - Single Locus Association HIV/HAART (-/-) 
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5.0  DISCUSSION 
Exposure to highly active antiretroviral therapy can have a number of metabolic side effects. The 
dyslipidemia observed in these patients is well-documented but varies in prevalence in any given 
population. We hypothesized that this variation was due to the genetic predisposition of 
individuals interacting with HAART and/or HIV infection. To test this hypothesis we designed a 
custom Illumina Golden Gate array consisting of candidate loci that had been associated with 
dyslipidemia and/or cardiovascular disease in the general population. We used this array to 
genotype 1,945 individuals enrolled in the Multicenter AIDS Cohort Study and performed 
genetic associations on four serum lipid phenotypes obtained from the MACS data. 
5.1 DYSLIPIDEMIA PHENOTYPES BY TREATMENT STATUS AND BGA 
Stratification of our population by biogeographical ancestry and subsequent examination of 
serum lipid levels, showed an intriguing result; the mean levels of some of the phenotypes tested 
varied by treatment status dependent on biogeographical ancestry. People from a particular 
ancestral population have different metabolic responses to HIV infection and HAART. Serum 
lipid levels are known to be different depending on race in the general population. Specifically, 
Whites have been shown to have higher TRIG levels than Blacks with Blacks having higher 
HDL-C levels and no difference in LDL-C or TCHOL compared to Whites42,43. In our control 
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population we observed that the EA and AEA populations had no significant difference in 
mTRIG or mHDL-C levels, yet we observed higher levels of mLDL-C and mTCHOL in the EA 
group compared to the AEA population. (Table 7) Indeed, when we formally tested this 
observation we found, that for every lipid phenotype we tested, biogeographical ancestry was a 
significant factor affecting mean serum lipid levels. The ANOVA results also showed that 
HIV/HAART status had significant effects on mean serum lipid levels for all phenotypes tested. 
The interaction term between HIV/HAART status and biogeographical ancestry was significant 
in two phenotypes, mLDL-C and mTRIG, but not significant for mHDL-C and mTCHOL. This 
suggests that there may be an interaction between HIV/HAART and biogeographical ancestry in 
affecting the mean serum levels of mLDL-C and mTRIG. We assume this interaction is due, at 
least in part, to shared genetic variants in a BGA group, yet other shared social, cultural, or 
environmental variants may also be contributing to this observed interaction. HIV/HAART (+/+) 
individuals of European ancestry had higher mean levels of mTRIG, mLDL-C, and mTCHOL 
when compared to the African/European population. HIV/HAART (+/+) individuals of African 
and European ancestry had higher mHDL-C levels when compared to the European population. 
These results support previous findings that HIV infection and HAART treatment results in 
dyslipidemia as well as offering a new understanding of the extent to which the degree of 
metabolic change depends on an individual’s biogeographical ancestry, presumably due to 
shared genetic susceptibility. Additionally these results help us characterize the different 
dyslipidemia profiles at the population level for each ancestral group. Specifically we see that 
HIV positive men of primarily European ancestry receiving HAART have lower mLDL-C and 
mHDL-C with higher mTRIG levels when compared to HIV/HAART (-/-) controls. HIV 
positive men of mixed African and European ancestry receiving HAART have a different 
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dyslipidemia profile consisting of only lower mLDL-C levels when compared to HIV/HAART (-
/-) controls. These results are encouraging because they hint at validating our initial hypothesis 
that dyslipidemia in HIV positive patients receiving HAART is in part due to genetic 
susceptibility, in this case biogeographical ancestry. 
5.2 GENETIC ASSOCIATIONS WITH SERUM LIPIDS 
We found a number of interesting and perhaps novel loci associated with mLDL-C and mHDL-C 
levels in HIV positive patients receiving HAART. The only locus we found to be associated with 
mLDL-C levels for either population was rs261334. This SNP is located in the first intron of 
LIPC on chromosome 15. The LIPC gene product, hepatic lipase, hydrolyzes phospholipids and 
triglycerides carried by lipoproteins in the serum as well as being a bridging factor for receptor-
mediated lipoprotein uptake in the liver. Polymorphisms in the promoter region of LIPC have 
previously been shown to be associated with cardiovascular disease and lipid metabolism123-125. 
Interestingly, the effects of hepatic lipase are usually associated with HDL-C and LDL-C particle 
size and density rather than serum levels of these lipoproteins, but in our study we have found 
that the rs261334 polymorphism is associated with lower serum mLDL-C levels in HIV/HAART 
(+/+) men of African and European ancestry compared to HIV/HAART (-/-) controls. This 
association between hepatic lipase and serum mLDL-C is novel and may be suggestive of some 
altered role or function due to HIV infection and/or HAART treatment. This is suggestively 
supported by the positive interaction of the rs261334 SNP in the HIV/HAART (+/+) population 
compared to the HIV/HAART (-/-) controls. The rs261334 polymorphism is in linkage 
disequilibrium with a number of SNPs in the 5’ and promoter regions of LIPC gene and may not 
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itself be the causative allele. The five other SNPs we found to be significantly associated with 
mHDL-C levels in both ancestral populations were in the CETP region on chromosome 16. In 
the men of European ancestry four SNPs (rs711752, rs708272, rs1532625, and rs1532624) and 
two haplotypes containing these four SNPs were found to be associated with increased mHDL-C 
levels. The CETP gene product transfers cholesterol esters from HDL-C to other lipoproteins, 
such as VLDL and LDL-C, in exchange for TRIG. CETP has been shown to be important in 
lipid metabolism relating to cardiovascular disease and can have pro- or anti-atherogenic effects. 
One of our associated SNPs, rs708272, is also known as TaqIB and is one of the oldest-known 
and most extensively studied polymorphisms in this gene126-128. The TaqIB variant does not alter 
the amino acid sequence of the CETP protein but is in strong LD with another SNP rs1800775, 
also known as -C629A, which is located in the promoter region of CETP and found to affect 
promoter activity directly. The LD in this gene makes it difficult to pinpoint a specific disease 
marker. In the European population all four of our significantly associated SNPs are in strong LD 
with each other.  Interestingly, in the African/European population these four SNPs failed to be 
associated with mHDL-C. Another SNP in CETP, rs4783961, was found to be significantly 
associated with mHDL-C in men of African and European ancestry. The LD structure in 
African/Europeans is weaker than in Europeans but it seems from the LD plot generated from 
our genotype data that rs4783961 polymorphism tags a similar region in CETP as those in the 
European population.  
 Of the four lipid phenotypes we tested, only mLDL-C and mHDL-C showed 
genetic associations. This could be due to a number of possibilities. There might be additional 
loci affecting these serum lipid levels that were not included on our array, or we may have not 
had sufficient power to detect the presumable small effect size present at each locus, which is 
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common in complex traits. Since we stratified our population by biogeographical ancestry and 
HIV/HAART status, the number of subjects in each test group did diminish. Despite this 
potential loss in power, we feel this stratification method best controls the bias introduced when 
performing genetic associations on admixed populations. Another possible reason for the lack of 
other associations may be that HAART causes such severe disturbances in cholesterol 
metabolism that any known genetic susceptibility to dyslipidemia or CVD has little effect. 
The MACS population consists of both HIV infected and HIV uninfected men. This 
provides a control population from which we can perform genetic associations with serum lipids 
and compare these results to those obtained from the HIV/HAART (+/+) population. Similarly to 
the HIV/HAART (+/+) population, we found associations in the CETP gene region with serum 
mHDL-C levels in men of European ancestry. Three of the SNPs; rs3764261, rs173539 and 
rs711752, are located in the promoter region of CETP and are in strong LD with the each other 
as well as the known clinically relevant SNPs rs708272 and rs1800775. One SNP, rs11076175, 
is located in the intron region of CETP. Although rs11076175 appears to be in high LD with the 
three other positively associated SNPs, its effect on serum mHDL-C is in the opposite direction 
to the three SNPs located in the promoter region. This may suggest a separate region of interest 
that has an association with decreased levels of mHDL-C in the HIV/HAART (-/-) men of 
European ancestry. These associations with decreased mHDL-C levels in the HIV/HAART (-/-) 
controls do not persist in the (+/+) test population. The association with increased serum levels 
of mHDL-C for these CETP polymorphisms appears similar across the HIV/HAART treatment 
groups and does not explain the observed lower mHDL-C levels seen in the HIV/HAART (+/+) 
compared to the (-/-) controls. 
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We also observed an association with increased serum mTRIG in a region on 
chromosome 11 in HIV/HAART (-/-) men of European ancestry.  This region contains a cluster 
of six genes; BUD13 homolog (BUD13), zinc finger protein 259 (ZNF259), apolipoprotein A-V 
(APOA5), apolipoprotein A-IV (APOA4), apolipoprotein C-III (APOC3), and apolipoprotein A-I 
(APOA1). Four SNPs in this region were significantly associated with increase mTRIG levels; 
rs2072560, rs964184, rs662799, rs9326246 and were located in or around the 
BUD13/ZNF259/APOA5 genes. Specifically, rs2072560 is located in an intron of APOA5, 
rs964184 is downstream proximal to the 3’-UTR of ZNF259, rs662799 is located in the 5’ 
promoter region of APOA5, and rs9326246 is downstream of BUD13. There is strong LD 
between these SNPs yet we hypothesize that APOA5 is the probably candidate explaining this 
association with serum mTRIG levels. It has been shown that polymorphisms in APOA5 have 
strong associations with TRIG concentrations and CVD risk in the general population129,130. In 
fact, one of our SNPs rs662799, is also known as T-1131>C and is one of the most widely 
studied polymorphisms in this gene. The fact that we identified this gene as being associated 
with serum mTRIG levels in HIV/HAART (-/-) men of European ancestry is not surprising. 
What is surprising, that even though the HIV/HAART (+/+) population had almost two fold 
higher levels of serum mTRIG levels, this gene cluster was not found to be significantly 
associated with mTRIG levels in the (+/+) men of European ancestry. This is evidence that the 
genes or mechanisms involved in the elevated mTRIG levels in HIV/HAART (+/+) patients may 
be novel and different than what has been identified in the general population.  
There are no statistically significant associations with any of the four serum lipid levels in 
HIV/HAART (-/-) men of African and European ancestry. This surprising result, along with the 
possible reasons for this lack of association, will be discussed in the following section. 
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5.3 UNANSWERED QUESTIONS AND LIMITATIONS 
While we have identified a number of SNPs associated with serum lipid levels in our 
HIV/HAART positive population, it is disconcerting we did not find more positive associations. 
In designing our study we selected for, what is generally thought to be, the most important 
reproducible genetic determinants associated with dyslipidemia and CVD in the general 
population. This candidate study approach should have led to a number of positive associations 
being identified, that fact that we failed to do so means we need to address the potential 
weaknesses and limitations present in our study. 
5.3.1 Over-Correction in Candidate Gene Association Studies 
The problem of false positive results in genetic association studies due to multiple independent 
comparisons is widely acknowledged. The current methods to correct for multiple comparisons 
include using a Bonferroni corrected p-value or a False Discovery Rate procedure. These 
procedures are often used in GWAS studies because there usually is no initial hypothesis to 
which genes may be associated with a given phenotype. A GWAS tests for thousands to millions 
of SNPs evenly distributed across the entire human genome to capture the maximum genetic 
variation present in a population.  
 In our study we chose to use a Bonferroni correction because we initially wanted to be as 
conservative as possible to limit our Type I error. Given our candidate loci approach this kind of 
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correction may be overly conservative because, unlike a GWAS, we had a defined set of 
hypotheses. We selected 267 SNPs that had been previously associated with dyslipidemia and 
CVD in the general population, we also selected 1,146 tagSNPs for 75 candidate genes we 
identified. By definition, these tagSNPs were selected based on their genetic correlation to other 
SNPs located in the gene but are generally independent of other tagSNPs. Even though these 
tagSNPs are mostly independent of each other they still may be in high LD with each other 
depending on the genetic correlation structure present in a gene. Using the Bonferroni correction 
for tests that are highly dependent, tagSNPs within a gene may be in high LD with other 
tagSNPs, is inappropriate and results in an overly conservative critical p-value. A better method 
for correction may be not to divide α by the n number of tests being performed but rather use an 
n for the number of independent loci being tested. Of course we are assuming these genes are 
independent of each other, biologically speaking, these gene products may be involved in shared 
physiological or cellular process and may impact the function and/or expression of each other 
directly. This would then violate the assumption of independence and thus it may be appropriate 
to use an even smaller n in correcting α for truly independent tests. Currently, there is no 
accepted method for assessing the true independence of loci being tested in a candidate gene 
study so we used a Bonferroni correction based on the number of tests performed with the 
understanding we are increasing the Type II error (false negatives) in our study. 
5.3.2 The Problem of Power 
The power of a study is the probability to reject the null hypothesis when the null hypothesis is 
false. The power and Type II error are directly related; in that power is equivalent to 1-β, where 
β is the Type II error. In our study we used a Bonferroni correction, which increases the Type II 
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error in favor of decreasing the study’s Type I error. Thus, we are intrinsically decreasing the 
power of our study because we want to limit the probability of falsely rejecting the null 
hypothesis. Statistical power is also dependent on other factors, such as the magnitude of effect 
being investigated and the sample size used to detect this effect. Generally, when trying to detect 
a small effect you need an increasingly large sample. Dyslipidemia is a complex human trait. 
Serum lipid levels are affected by a number of different genes with varying effects sizes. Given 
the lack of positive associations in our study, we may have been underpowered to detect the 
effect of genes we tested for, either because of our stringent statistical correction or smaller than 
needed sample size. Ideally we would like to genotype SNPs with the strongest associations in 
the remaining MACS population to valid our results and to increase the power to detect genes 
with important but small effects. 
5.4 FUTURE WORK 
5.4.1 Investigating Gene Expression 
Our association results identified a number of SNPs associated with altered serum lipid levels in 
HIV/HAART positive individuals. The SNPs we identified are in strong LD with known variants 
in the promoter regions of CETP and LIPC. This suggests that the genetic variation we found to 
be associated with serum lipid levels is related to the expression and thus the protein levels of the 
genes we have identified, primarily through alterations in promoter activity. We hypothesize the 
mechanism by which these genes affect serum lipids are as follows and outlined in Figure 16: 
SNPs associated with decreased CETP expression could results in the observed association with 
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increased HDL-C and SNPs associated with increased expression of LIPC could ultimately result 
in the observed association of decreased LDL-C, through an intermediate step involving HDL-C. 
The fact that, familial CETP deficiency is characterized by increased levels of HDL-C supports 
our first mechanistic hypothesis that decreased levels of CETP may explain the association with 
increased HDL-C. In contrast, LIPC (hepatic lipase) is more often implicated in receptor 
mediated HDL-C uptake at the liver and modulations in LDL-C particle size and density. The 
association with decreased LDL-C may be a novel insight to LIPC’s role in lipid metabolism, 
especially in our unique population. 
 
Figure 16 - Possible Mechanisms of CETP and LIPC 
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To formally investigate these potential mechanisms of action we have two options that 
are currently available to us, which focus on expression levels of CETP and LIPC. The first 
technique we could employ would be to use a luciferase-reporter gene assay. In this experiment 
the candidate promoter region containing the SNPs of interest are cloned into reporter vectors 
containing gene/s downstream of the promoter then when transcribed, produce a luminescent 
protein. The luminescence of the protein can be read and compared to a wild-type control. If the 
mutant promoter alters the transcriptional activity, its luminescence will be different (higher or 
lower) compared to the wild-type. The second method is one our lab is already performing, RNA 
transcriptome studies. In these experiments RNA is extracted from patient PBMCs and run on a 
RNA microarray. The microarray reports relative expression levels of over 30k known RNA 
transcripts. We can take this raw data and compare people who possess the SNPs of interest to 
people who do not possess these SNPs. In this way we can see if there is a relative difference in 
expression of CETP and LIPC associated with the proposed altered promoter function. 
 
5.4.2 Genetic Associations on Additional MACS Phenotypes 
The main outcomes of our study were serum lipid levels that we associated with dyslipidemia in 
HIV infected individuals receiving HAART. Even though we focused on dyslipidemia in this 
study, we ultimately are interested in the relationship of these lipids to CVD risk in our 
population. Serum lipids are not the only biological phenotypes we can investigate; there are a 
number of CVD risk surrogates, which are indicators of subclinical atherosclerosis. A recent 
study was done by Kingsley et al.71, in which they investigated coronary artery calcification 
(CAC) in HIV/HAART positive patients in the Pittsburgh Men’s Study (PMS), a subset of the 
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MACS. We would like to use our genotype data for the PMS participants to investigate the 
possible association of lipid metabolism and inflammatory genes to CAC development in 
HIV/HAART positive patients. 
As discussed in the introduction, cholesterol availability is critical to the HIV lifecycle. 
HIV employs a number of strategies to modulate and sequester cellular cholesterol during its 
infection. We are interested in the possibility that people with different SNPs in cholesterol 
metabolism genes may respond to HIV infection in different ways. Specifically we are interested 
to see if our SNPs are associated with HIV disease progression, including; viral load, years to 
first reported AIDS symptoms, and rapid versus long-term non progression. 
5.5 PUBLIC HEALTH IMPACT AND SIGNIFICANCE 
We are the first to show that dyslipidemia in HIV positive men receiving HAART differs on the 
basis of biogeographical ancestry. We also report the first characterization of the dyslipidemia 
profiles in these patients at the population level. We hypothesized that the dyslipidemia seen in 
this population was due to a preexisting genetic susceptibility. Our results show that for two of 
the phenotypes tested a genetic association is present and these associations appear different in 
each ancestral population. Interestingly, only the polymorphism in LIPC in the African/European 
population agrees with the observed changes in serum mLDL-C levels of HIV positive men 
receiving HAART. These results advance our understanding of the mechanism of HAART-
associated dyslipidemia and may lead to improved treatment of these patients. For example, our 
data show that HAART-associated dyslipidemia varies by BGA. In fact, HIV/HAART (+/+) men 
of African and European ancestry seem to develop an anti-atherogenic lipid profile characterized 
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by lower levels of LDL-C, which was the only serum lipid we tested that was significantly 
different than (-/-) controls for this population. This implies that any prophylaxis treatment with 
statins for HIV/HAART (+/+) men of mixed African and European ancestry would be 
unnecessary. Obviously it is important for physicians to treat high LDL-C levels with statins on a 
case by case basis, but our data show that LDL-C levels of HIV/HAART (+/+) men was lower 
on average when compared to (-/-) controls suggesting that HAART may not actually be 
increasing CVD risk mediated by increasing LDL-C levels. Rather, this observed increase 
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Kosoy et al. - 2009 
rs4845882 1 11765754 
  
Y 
 rs1537516 1 11770448 
  
Y 
 rs4846049 1 11772952 
  
Y 
 rs1476413 1 11774887 
  
Y 
 rs12121543 1 11777258 
  
Y 
 rs1801133 1 11778965 
  
Y 
 rs7533315 1 11783270 
  
Y 
 rs17037397 1 11784750 
  
Y 
 rs17367504 1 11785365 
  
Y 
 rs2066472 1 11785558 
  
Y 




Kosoy et al. - 2009 




Kosoy et al. - 2009 
rs10903129 1 25641524 Y 
  
Aulchenko et al. - 2009 




Kosoy et al. - 2009 




Kosoy et al. - 2009 
rs11206510 1 55268627 Y 
  
Willer et al. - 2008, Kathiresan et al. - 2008, Aulchenko et al. - 
2009 
rs7525649 1 55271744 
  
Y 
 rs2495488 1 55272794 
  
Y 
 rs2479409 1 55277238 
  
Y 
 rs4927193 1 55282460 
  
Y 
 rs499718 1 55285137 
  
Y 
 rs2479412 1 55286661 
  
Y 
 rs11206514 1 55288592 
  
Y 
 rs572512 1 55289932 
  
Y 
 rs7552841 1 55291340 
  
Y 
 rs557435 1 55293452 
  
Y 





rs615563 1 55298884 
  
Y 
 rs10465832 1 55301395 
  
Y 
 rs505151 1 55301775 
  
Y 
 rs17111555 1 55302190 
  
Y 
 rs662145 1 55302416 
  
Y 
 rs13312 1 55305330 
  
Y 




Kosoy et al. - 2009 
rs1167998 1 62704220 Y 
  
Aulchenko et al. - 2009 
rs10493326 1 62725961 
  
Y 
 rs1168026 1 62743584 
  
Y 
 rs17123694 1 62753688 
  
Y 
 rs13375691 1 62768961 
  
Y 
 rs1748195 1 62822181 Y 
  
Willer et al. - 2008 
rs11207998 1 62864059 
  
Y 
 rs10889353 1 62890784 Y 
  
Aulchenko et al. - 2009, Kathiresan et al. - 2009 
rs912540 1 62907715 
  
Y 
 rs12130333 1 62964365 Y 
  
Kathiresan et al. - 2009 
rs12080049 1 63012419 
  
Y 
 rs17123828 1 63020039 
  
Y 
 rs17316381 1 63046891 
  
Y 
 rs17388604 1 63103662 
  
Y 
 rs1413242 1 63104452 
  
Y 
 rs1892534 1 65878532 Y 
   rs12753193 1 65942267 Y 
  
Sabatti et al. - 2009 




Kosoy et al. - 2009 
rs4584412 1 100954164 
  
Y 
 rs1409419 1 100955984 
  
Y 
 rs3176860 1 100959807 
  
Y 
 rs3176861 1 100959909 
  
Y 
 rs3917009 1 100961998 
  
Y 
 rs3917012 1 100968247 
  
Y 
 rs3176870 1 100969771 
  
Y 
 rs3176871 1 100969877 
  
Y 
 rs3917014 1 100969972 
  
Y 
 rs3917016 1 100973735 
  
Y 
 rs3176877 1 100975983 
  
Y 
 rs3176878 1 100976286 
  
Y 
 rs3783621 1 100977083 
  
Y 
 rs10493936 1 100985923 
  
Y 




Kosoy et al. - 2009 
rs4623734 1 109584728 
  
Y 
 rs4246519 1 109585078 
  
Y 
 rs17035415 1 109589016 
  
Y 
 rs585362 1 109591318 
  
Y 
 rs437444 1 109597131 
  
Y 
 rs10858082 1 109600244 
  
Y 
 rs626387 1 109600326 
  
Y 
 rs6689614 1 109608622 
  
Y 
 rs6657811 1 109608806 Y 
  
Sandhu et al. - 2008 
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rs17035665 1 109615242 
  
Y 
 rs4970834 1 109616403 Y 
  
Sandhu et al. - 2008 
rs611917 1 109616775 Y 
  
Sandhu et al. - 2008 
rs12740374 1 109619113 Y 
  
Kathiresan et al. - 2009 
rs660240 1 109619361 Y 
  
Sandhu et al. - 2008 
rs646776 1 109620053 Y 
  
Kathiresan et al. - 2008, Sabatti et al. - 2009, Aulchenko et al. - 
2009 
rs17035949 1 109622442 
  
Y 
 rs602633 1 109623034 Y 
  
Willer et al. - 2008 
rs599839 1 109623689 Y 
  
Willer et al. - 2008, Kathiresan et al. - 2008 
rs657420 1 109627659 
  
Y 
 rs17584208 1 109634710 
  
Y 
 rs17645143 1 109637280 
  
Y 
 rs3850615 1 109641261 
  
Y 
 rs7515901 1 109641419 
  
Y 
 rs443345 1 109650777 
  
Y 
 rs464218 1 109657829 
  
Y 
 rs11102972 1 109682244 
  
Y 
 rs7536292 1 109696216 
  
Y 
 rs17646665 1 109713574 
  
Y 




Kosoy et al. - 2009 
rs2228145 1 151240043 
  
Y 
 rs4129267 1 152692888 Y 
   rs2794520 1 157945440 Y 
  
Sabatti et al. - 2009 
rs3093077 1 157946260 
  
Y 
 rs2808630 1 157947492 
  
Y 
 rs1205 1 157948857 
  
Y 
 rs1130864 1 157949715 
  
Y 
 rs1800947 1 157950062 Y 
  
Sabatti et al. - 2009 
rs3737787 1 159276147 
  
Y 
 rs2774276 1 159278340 
  
Y 
 rs2073653 1 159279384 
  
Y 
 rs2516837 1 159281351 
  
Y 
 rs2774279 1 159284180 
  
Y 




Kosoy et al. - 2009 
rs12120904 1 167744666 
  
Y 
 rs10919181 1 167744885 
  
Y 
 rs2420369 1 167752483 
  
Y 
 rs9332649 1 167757803 
  
Y 
 rs9332629 1 167764238 
  
Y 
 rs9332623 1 167764984 
  
Y 
 rs1557572 1 167775200 
  
Y 
 rs6016 1 167778744 
  
Y 
 rs9332595 1 167780979 
  
Y 
 rs6035 1 167788473 
  
Y 
 rs12120605 1 167789178 
  
Y 
 rs6427198 1 167789873 
  
Y 
 rs6427199 1 167790161 
  
Y 
 rs9332579 1 167791936 
  
Y 





rs6427203 1 167795655 
  
Y 
 rs2298905 1 167805466 
  
Y 
 rs10489184 1 167815664 
  
Y 
 rs6703462 1 167817214 
  
Y 
 rs3753305 1 167820682 
  
Y 
 rs3917854 1 167825659 
  
Y 
 rs6128 1 167829528 
  
Y 
 rs1569471 1 167830754 
  
Y 
 rs3766122 1 167833451 
  
Y 
 rs3917793 1 167834169 
  
Y 
 rs760694 1 167835322 
  
Y 
 rs2420378 1 167836542 
  
Y 
 rs3917779 1 167837472 
  
Y 
 rs3917744 1 167844614 
  
Y 
 rs2076074 1 167845210 
  
Y 
 rs3917740 1 167845890 
  
Y 
 rs3917739 1 167846002 
  
Y 
 rs2235305 1 167846269 
  
Y 
 rs2235302 1 167846914 
  
Y 
 rs6131 1 167847509 
  
Y 
 rs3917727 1 167847882 
  
Y 
 rs3917709 1 167851169 
  
Y 
 rs2244529 1 167853656 
  
Y 
 rs3917698 1 167854741 
  
Y 
 rs3917688 1 167857704 
  
Y 
 rs3917676 1 167859135 
  
Y 
 rs3917657 1 167865366 
  
Y 
 rs3917651 1 167866686 
  
Y 
 rs6691334 1 167869007 
  
Y 
 rs12401978 1 167871409 
  
Y 
 rs1569476 1 167875541 
  
Y 
 rs1053381 1 169311944 Y 
   rs4648304 1 184907476 
  
Y 
 rs689470 1 184907681 
  
Y 
 rs5275 1 184909681 
  
Y 
 rs2745557 1 184915844 
  
Y 
 rs689466 1 184917374 
  
Y 
 rs12042763 1 184918499 
  
Y 
 rs2143417 1 184920410 
  
Y 
 rs3024505 1 205006527 
  
Y 
 rs1554286 1 205010856 
  
Y 
 rs1518111 1 205011268 
  
Y 
 rs1800893 1 205013790 
  
Y 
 rs1800890 1 205015988 
  
Y 
 rs10494879 1 205018827 
  
Y 
 rs4844614 1 205941798 Y 
  
Sabatti et al. - 2009 




Kosoy et al. - 2009 
rs17465637 1 220890152 Y 
  
Samani et al. - 2007 





rs1321258 1 228268651 
  
Y 
 rs7531967 1 228273972 
  
Y 
 rs2883025 1 228274995 
  
Y 
 rs6684432 1 228276413 
  
Y 
 rs6541267 1 228277868 
  
Y 
 rs6673349 1 228278021 
  
Y 
 rs11122275 1 228279156 
  
Y 
 rs910820 1 228280942 
  
Y 
 rs16850871 1 228286093 
  
Y 
 rs16850878 1 228289864 
  
Y 
 rs10495293 1 228293369 
  
Y 
 rs12029443 1 228293831 
  
Y 
 rs7536663 1 228295422 
  
Y 
 rs12035297 1 228305444 
  
Y 
 rs7527527 1 228307777 
  
Y 
 rs1474839 1 228308023 
  
Y 
 rs10489614 1 228313992 
  
Y 
 rs7550262 1 228315362 
  
Y 
 rs2144296 1 228330458 
  
Y 
 rs7538126 1 228330685 
  
Y 
 rs1973943 1 228338686 
  
Y 
 rs11122383 1 228339548 
  
Y 
 rs6690424 1 228345515 
  
Y 
 rs4846908 1 228351679 
  
Y 
 rs1998064 1 228353751 
  
Y 
 rs2144300 1 228361539 Y 
  
Aulchenko et al. - 2009, Willer et al. - 2008 
rs4846914 1 228362314 Y 
  
Kathiresan et al. - 2008, Willer et al. - 2008 
rs10127775 1 228362412 
  
Y 
 rs2281722 1 228363666 
  
Y 
 rs609526 1 228375529 
  
Y 
 rs1124110 1 228377595 
  
Y 
 rs678050 1 228380534 
  
Y 
 rs611229 1 228390690 
  
Y 
 rs612577 1 228390987 
  
Y 
 rs6677241 1 228404510 
  
Y 
 rs4846928 1 228408528 
  
Y 
 rs4846934 1 228414355 
  
Y 
 rs16851142 1 228418757 
  
Y 
 rs1980533 1 228435573 
  
Y 
 rs3811488 1 228438506 
  
Y 
 rs3811486 1 228438684 
  
Y 
 rs11122474 1 228445305 
  
Y 
 rs6688678 1 228447910 
  
Y 
 rs3789630 1 228454121 
  
Y 
 rs901675 1 228456625 
  
Y 
 rs11588358 1 228475681 
  
Y 
 rs17761459 1 228476185 
  
Y 
 rs7533085 1 228476247 
  
Y 





rs6698963 1 228481648 
  
Y 
 rs2273970 1 228481771 
  
Y 
 rs2273968 1 228481867 
  
Y 
 rs13728 1 228482841 
  
Y 
 rs1043908 1 228483917 
  
Y 
 rs1043944 1 228484183 
  
Y 
 rs7022 1 228484287 
  
Y 
 rs9431818 1 228484622 
  
Y 
 rs12757317 1 228485931 
  
Y 
 rs4846948 1 228486993 
  
Y 
 rs6541309 1 228488126 
  
Y 
 rs6687864 1 228488345 
  
Y 
 rs17762687 1 228488654 
  
Y 
 rs10864734 1 228488833 
  
Y 
 rs11122478 1 228490104 
  
Y 
 rs1998486 1 228491370 
  
Y 
 rs7536290 1 228903325 
  
Y 
 rs10864771 1 228904295 
  
Y 
 rs7079 1 228904954 
  
Y 
 rs2478523 1 228908132 
  
Y 
 rs3789664 1 228910047 
  
Y 
 rs2493131 1 228910128 
  
Y 
 rs2478545 1 228910744 
  
Y 
 rs6687360 1 228911615 
  
Y 
 rs699 1 228912417 Y 
  
Willer et al. - 2008, Tsai et al. - 2009 
rs4762 1 228912600 Y 
  
Tsai et al. - 2009 
rs11568028 1 228913867 
  
Y 
 rs2004776 1 228915325 
  
Y 
 rs3889728 1 228915454 
  
Y 
 rs1078499 1 228915719 
  
Y 
 rs7539020 1 228915813 
  
Y 
 rs2493134 1 228915982 
  
Y 
 rs3789678 1 228916105 
  
Y 
 rs2148582 1 228916422 
  
Y 
 rs11122580 1 228917667 
  
Y 
 rs2493137 1 228918739 
  
Y 
 rs7549009 1 228921694 
  
Y 
 rs16831987 1 235020410 
  
Y 
 rs12097647 1 235060752 
  
Y 
 rs7541539 1 235079167 
  
Y 
 rs10802564 1 235088700 
  
Y 
 rs10495387 1 235103880 
  
Y 
 rs10925257 1 235112783 
  
Y 
 rs12049580 1 235123532 
  
Y 
 rs6679990 1 235131853 
  
Y 




Kosoy et al. - 2009 




Kosoy et al. - 2009 




Kosoy et al. - 2009 
rs6754295 2 21059688 Y 
  
Aulchenko et al. - 2009 
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rs7557067 2 21061717 Y 
  
Kathiresan et al. - 2009 
rs13392272 2 21070995 
  
Y 
 rs4371387 2 21074638 
  
Y 
 rs1042034 2 21078786 Y 
  
Knoblauch et al. - 2004 
rs1801702 2 21078990 
  
Y 
 rs1801703 2 21079417 Y 
  
Knoblauch et al. - 2004 
rs1800479 2 21080888 Y 
  
Knoblauch et al. - 2004 




rs693 2 21085700 Y 
  
Aulchenko et al. - 2009, Kathiresan et al. - 2008, Knoblauch et 
al. - 2004, Sabatti et al. - 2009, Willer et al. - 2008 
rs533617 2 21087477 
  
Y 




rs673548 2 21091049 Y 
  
Aulchenko et al. - 2009, Knoblauch et al. - 2004, Sabatti et al. - 
2009 
rs12713844 2 21091918 
  
Y 
 rs11126598 2 21093869 
  
Y 
 rs12713911 2 21094043 
  
Y 
 rs12713956 2 21095010 
  
Y 
 rs10199768 2 21097505 
  
Y 
 rs11676704 2 21097863 
  
Y 
 rs12720791 2 21098122 
  
Y 
 rs7589300 2 21098265 
  
Y 
 rs1801700 2 21099318 
  
Y 
 rs679899 2 21104419 Y 
  
Knoblauch et al. - 2004 
rs12720832 2 21110218 
  
Y 
 rs520354 2 21113117 Y 
  
Knoblauch et al. - 2004 
rs1800478 2 21113641 
  
Y 
 rs12720796 2 21115503 
  
Y 
 rs531819 2 21117144 
  
Y 
 rs1367117 2 21117405 Y 
  
Knoblauch et al. - 2004 
rs512535 2 21121287 Y 
  
Knoblauch et al. - 2004 
rs17398765 2 21124256 
  
Y 
 rs1713222 2 21124828 Y 
  
Sandhu et al. - 2008 
rs7575840 2 21126995 Y 
  
Kathiresan et al. - 2008 
rs11893021 2 21127083 
  
Y 
 rs11892073 2 21129906 
  
Y 
 rs515135 2 21139562 Y 
  
Kathiresan et al. - 2009, Willer et al. - 2008 
rs562338 2 21141826 Y 
  
Willer et al. - 2008 
rs754523 2 21165196 Y 
  
Willer et al. - 2008 
rs4591370 2 21237247 Y 
  
Sandhu et al. - 2008 
rs538928 2 21242524 Y 
  
Sandhu et al. - 2008 
rs488507 2 21247194 Y 
  
Sandhu et al. - 2008 
rs506585 2 21250687 Y 
  
Sandhu et al. - 2008 
rs478442 2 21252721 Y 
  
Sandhu et al. - 2008 




rs1260326 2 27584444 Y 
  
Kathiresan et al. - 2009, Willer et al. - 2008, Sabatti et al. - 
2009 
rs780094 2 27594741 Y 
  
Aulchenko et al. - 2009, Willer et al. - 2008, Knoblauch et al. - 
2008 
rs4665987 2 27609329 
  
Y 
 rs11127129 2 27930212 Y 
  
Willer et al. - 2008 




Kosoy et al. - 2009 
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Kosoy et al. - 2009 
rs10180615 2 43892201 
  
Y 
 rs4148195 2 43893137 
  
Y 
 rs2278356 2 43893379 
  
Y 
 rs4148191 2 43896408 
  
Y 
 rs4953019 2 43896897 
  
Y 
 rs10205816 2 43897759 
  
Y 
 rs4148189 2 43901034 
  
Y 
 rs10439467 2 43901850 
  
Y 
 rs1864814 2 43902095 
  
Y 
 rs4245786 2 43902624 
  
Y 
 rs4073237 2 43903376 
  
Y 
 rs4148188 2 43904191 
  
Y 
 rs4289236 2 43907627 
  
Y 
 rs4148185 2 43909826 
  
Y 
 rs4953020 2 43916400 
  
Y 
 rs6756629 2 43918594 Y 
  
Aulchenko et al. - 2009 
rs11887534 2 43919751 Y 
  
Kathiresan et al. - 2009 
rs4148202 2 43921323 
  
Y 
 rs4148208 2 43923898 
  
Y 
 rs4299376 2 43926080 
  
Y 
 rs6544713 2 43927385 Y 
  
Kathiresan et al. - 2009 
rs4953023 2 43927504 Y 
  
Kathiresan et al. - 2009 
rs4148214 2 43932508 
  
Y 
 rs6709904 2 43933828 
  
Y 
 rs6755809 2 43949840 
  
Y 
 rs4148217 2 43952937 
  
Y 
 rs12468591 2 43953519 
  
Y 
 rs6756676 2 43953673 
  
Y 
 rs4245794 2 43954353 
  
Y 
 rs4953028 2 43955331 
  
Y 
 rs4148221 2 43955995 
  
Y 
 rs4148222 2 43956138 
  
Y 
 rs2954804 2 43961246 
  
Y 
 rs2954805 2 43962662 
  
Y 
 rs2954806 2 43962785 
  
Y 
 rs4953029 2 43963011 
  
Y 
 rs4352264 2 55941781 
  
Y 
 rs11694213 2 55942171 
  
Y 
 rs1346787 2 55946116 
  
Y 
 rs17278665 2 55949498 
  
Y 
 rs7563085 2 55956674 
  
Y 
 rs1346786 2 55961837 
  
Y 
 rs3791675 2 55964813 
  
Y 
 rs3791673 2 55967042 
  
Y 
 rs1430193 2 55974357 
  
Y 
 rs3791668 2 55975497 
  
Y 
 rs3791661 2 55983374 
  
Y 





rs960993 2 55989732 
  
Y 
 rs3791656 2 55995226 
  
Y 
 rs2868440 2 56012150 
  
Y 




Kosoy et al. - 2009 




Kosoy et al. - 2009 
rs3917368 2 113299253 
  
Y 
 rs2853550 2 113303592 
  
Y 
 rs1143634 2 113306861 
  
Y 
 rs1143630 2 113308126 
  
Y 
 rs1143627 2 113310858 
  
Y 
 rs13032029 2 113316886 
  
Y 
 rs928940 2 113593966 
  
Y 
 rs1794066 2 113602821 
  
Y 
 rs579543 2 113606102 
  
Y 
 rs315951 2 113607057 
  
Y 
 rs397211 2 113608612 
  
Y 
 rs315948 2 113609727 
  
Y 
 rs11885498 2 113616648 
  
Y 
 rs315958 2 113617322 
  
Y 




Kosoy et al. - 2009 
rs560887 2 169471394 Y 
  
Sabatti et al. - 2009 




Kosoy et al. - 2009 




Kosoy et al. - 2009 
rs2943634 2 226776324 Y 
  
Samani et al. - 2007 




Kosoy et al. - 2009 




Kosoy et al. - 2009 
rs5875 3 38139378 
  
Y 
 rs156265 3 38145814 
  
Y 
 rs2239621 3 38148737 
  
Y 
 rs7625290 3 38153294 
  
Y 
 rs172111 3 38162998 
  
Y 




Kosoy et al. - 2009 
rs1799864 3 46374212 Y 




Kosoy et al. - 2009 
rs5868 3 120413481 Y 
   rs12695382 3 120430861 Y 
  
Willer et al. - 2008 




Kosoy et al. - 2009 
rs1055419 3 126796272 Y 




Kosoy et al. - 2009 




Kosoy et al. - 2009 
rs409742 3 149895055 
  
Y 
 rs10935724 3 149903943 
  
Y 
 rs718858 3 149918202 
  
Y 
 rs1492099 3 149920193 
  
Y 
 rs12721241 3 149924310 
  
Y 
 rs389566 3 149929072 
  
Y 
 rs385338 3 149931846 
  
Y 
 rs12721298 3 149934037 
  
Y 





rs5182 3 149942085 
  
Y 
 rs275645 3 149947144 
  
Y 
 rs275644 3 149948230 
  
Y 
 rs275643 3 149948294 
  
Y 
 rs275642 3 149948381 
  
Y 
 rs427832 3 149949053 
  
Y 
 rs2261950 3 149950955 
  
Y 




Kosoy et al. - 2009 




Kosoy et al. - 2009 
rs17132047 4 1697184 Y 
   rs735794 4 2809236 
  
Y 
 rs9715869 4 2809457 
  
Y 
 rs12503220 4 2819940 
  
Y 
 rs16843487 4 2831761 
  
Y 
 rs17833172 4 2838312 
  
Y 
 rs2032470 4 2843633 
  
Y 
 rs7689864 4 2845194 
  
Y 
 rs2097081 4 2850907 
  
Y 
 rs3755885 4 2857739 
  
Y 
 rs3775068 4 2858239 
  
Y 
 rs2237004 4 2867072 
  
Y 




Kosoy et al. - 2009 




Kosoy et al. - 2009 




Kosoy et al. - 2009 




Kosoy et al. - 2009 




Kosoy et al. - 2009 




Kosoy et al. - 2009 




Kosoy et al. - 2009 




Kosoy et al. - 2009 
rs1801394 5 7923973 
  
Y 
 rs7730643 5 7928963 
  
Y 
 rs3776467 5 7929315 
  
Y 
 rs326122 5 7929611 
  
Y 
 rs7703033 5 7932950 
  
Y 
 rs162031 5 7933287 
  
Y 
 rs162033 5 7933835 
  
Y 
 rs3815743 5 7940109 
  
Y 
 rs2287780 5 7942304 
  
Y 
 rs1802059 5 7950319 
  
Y 
 rs8659 5 7953833 
  
Y 
 rs7715062 5 7959907 
  
Y 
 rs327588 5 7961359 
  
Y 
 rs162270 5 7962907 
  
Y 




Kosoy et al. - 2009 




Kosoy et al. - 2009 
rs33445 5 52317671 
  
Y 
 rs27377 5 52325134 
  
Y 
 rs6867926 5 52326815 
  
Y 





rs35235 5 52327994 
  
Y 
 rs35236 5 52328312 
  
Y 
 rs10071255 5 52336624 
  
Y 
 rs16880636 5 52336848 
  
Y 
 rs6859355 5 52337473 
  
Y 
 rs153141 5 52340753 
  
Y 
 rs1421940 5 52341770 
  
Y 
 rs3212418 5 52351929 
  
Y 
 rs7735277 5 52354673 
  
Y 
 rs246406 5 52354833 
  
Y 
 rs7705328 5 52359325 
  
Y 
 rs3212433 5 52372901 
  
Y 
 rs3212435 5 52373083 
  
Y 
 rs3212476 5 52379113 
  
Y 
 rs3212541 5 52393232 
  
Y 
 rs3212545 5 52394794 
  
Y 
 rs2303122 5 52415034 
  
Y 
 rs3212627 5 52416680 
  
Y 
 rs1109527 5 52422907 
  
Y 
 rs12518145 5 52427607 
  
Y 
 rs4492095 5 74353035 
  
Y 
 rs12655792 5 74367747 
  
Y 
 rs7708899 5 74368733 
  
Y 
 rs3761739 5 74667257 
  
Y 
 rs2303152 5 74677463 
  
Y 
 rs11742194 5 74682634 
  
Y 
 rs12654264 5 74684359 Y 
  
Kathiresan et al. - 2008, two papers this year 
rs10063134 5 74685405 
  
Y 
 rs3846662 5 74686840 Y 
  
Aulchenko et al. - 2009 
rs5908 5 74687955 
  
Y 
 rs7717396 5 74690535 
  
Y 
 rs3846663 5 74691482 Y 
  
Kathiresan et al. - 2009 
rs10474435 5 74693036 
  
Y 
 rs4703670 5 74696112 
  
Y 
 rs16872523 5 74701432 
  
Y 
 rs5744612 5 74885225 
  
Y 
 rs5744665 5 74911800 
  
Y 
 rs4703674 5 74918437 
  
Y 
 rs5744707 5 74926374 
  
Y 
 rs5744712 5 74927758 
  
Y 
 rs2287711 5 74934508 
  
Y 




Kosoy et al. - 2009 
rs7721577 5 139985970 
  
Y 
 rs2569190 5 139993100 
  
Y 
 rs5744451 5 139994067 
  
Y 
 rs2569193 5 139995679 
  
Y 
 rs11959615 5 148181509 
  
Y 
 rs17778257 5 148184770 
  
Y 





rs1042719 5 148187640 
  
Y 
 rs7702861 5 148192051 
  
Y 
 rs12652757 5 148194422 
  
Y 
 rs17108817 5 148196095 
  
Y 
 rs11957757 5 148196380 
  
Y 




Kosoy et al. - 2009 
rs1501908 5 156330747 Y 
  
Kathiresan et al. - 2009 




Kosoy et al. - 2009 




Kosoy et al. - 2009 




Kosoy et al. - 2009 




Kosoy et al. - 2009 




Kosoy et al. - 2009 
rs915654 6 31646476 
  
Y 
 rs2239704 6 31648120 
  
Y 
 rs3093542 6 31648672 
  
Y 
 rs1041981 6 31648763 
  
Y 
 rs1799964 6 31650287 
  
Y 
 rs1800630 6 31650455 
  
Y 
 rs1800629 6 31651010 
  
Y 
 rs3093662 6 31652168 
  
Y 
 rs3093671 6 31654959 
  
Y 
 rs769178 6 31655493 
  
Y 
 rs2254287 6 33251926 Y 
  
Willer et al. - 2008 




Kosoy et al. - 2009 




Kosoy et al. - 2009 
rs7646 6 151464443 Y 
   rs4869817 6 154508510 Y 
   rs3127596 6 160873025 
  
Y 
 rs7449650 6 160877104 
  
Y 
 rs9457933 6 160877759 
  
Y 
 rs3798220 6 160881127 Y 
  
Kathiresan et al. - 2009 
rs10755578 6 160889728 
  
Y 
 rs7761293 6 160890953 
  
Y 
 rs9364559 6 160896138 
  
Y 
 rs6415084 6 160900320 
  
Y 
 rs3798221 6 160918138 
  
Y 
 rs7771801 6 160928105 
  
Y 
 rs7770628 6 160938164 
  
Y 
 rs13202636 6 160949718 
  
Y 
 rs9355814 6 160951243 
  
Y 
 rs7759633 6 160990980 
  
Y 
 rs1367210 6 161002789 
  
Y 
 rs9346833 6 161004632 
  
Y 
 rs783149 6 161008908 
  
Y 
 rs1406888 6 161011583 
  
Y 




Kosoy et al. - 2009 




Kosoy et al. - 2009 




Kosoy et al. - 2009 
rs10244051 7 15030358 Y 
  
Sabatti et al. - 2009 
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rs2191348 7 15030780 Y 
  
Sabatti et al. - 2009 
rs12670798 7 21573877 Y 
  
Aulchenko et al. - 2009 
rs7801617 7 22724607 
  
Y 
 rs7805828 7 22725087 
  
Y 
 rs2056576 7 22727727 
  
Y 
 rs12700386 7 22729534 
  
Y 
 rs1800796 7 22732771 
  
Y 
 rs2069835 7 22734396 
  
Y 
 rs2069840 7 22735097 
  
Y 
 rs2069852 7 22738785 
  
Y 
 rs10242595 7 22740756 
  
Y 




Kosoy et al. - 2009 




Kosoy et al. - 2009 
rs2237281 7 72483987 
  
Y 
 rs2240466 7 72494205 Y 
  
Aulchenko et al. - 2009 
rs2237279 7 72499785 
  
Y 
 rs714052 7 72502805 Y 
  
Kathiresan et al. - 2009 
rs12056034 7 72516581 
  
Y 
 rs2074754 7 72529690 Y 
   rs2353082 7 72551104 
  
Y 
 rs17145721 7 72572016 
  
Y 
 rs17145738 7 72620810 Y 
  
Kathiresan et al. - 2008, Willer et al. - 2008 
rs14415 7 72622716 
  
Y 
 rs11974409 7 72627326 
  
Y 
 rs11760752 7 72660998 
  
Y 
 rs17145813 7 72684694 
  
Y 
 rs13230514 7 72686031 
  
Y 




Kosoy et al. - 2009 
rs10499859 7 80096746 Y 
  
Love-Gregory et al. - 2008 
rs13438282 7 80100160 Y 
  
Love-Gregory et al. - 2008 
rs9784998 7 80100937 Y 
  
Love-Gregory et al. - 2008 
rs1049654 7 80113391 Y 
  
Love-Gregory et al. - 2008 
rs3211810 7 80114953 Y 
  
Love-Gregory et al. - 2008 
rs3211842 7 80120572 Y 
  
Love-Gregory et al. - 2008 
rs3211849 7 80121259 Y 
  
Love-Gregory et al. - 2008 
rs3211850 7 80121352 Y 
  
Love-Gregory et al. - 2008 
rs1054516 7 80122878 Y 
  
Love-Gregory et al. - 2008 
rs3173798 7 80123786 Y 
  
Love-Gregory et al. - 2008 
rs3211868 7 80124958 Y 
  
Love-Gregory et al. - 2008 
rs3211870 7 80125145 Y 
  
Love-Gregory et al. - 2008 
rs1358337 7 80126321 Y 
  
Love-Gregory et al. - 2008 
rs3211909 7 80132051 Y 
  
Love-Gregory et al. - 2008 
rs3211913 7 80132540 Y 
  
Love-Gregory et al. - 2008 
rs3173804 7 80137786 Y 
  
Love-Gregory et al. - 2008 
rs3211938 7 80138385 Y 
  
Love-Gregory et al. - 2008 
rs7755 7 80144207 Y 
  
Love-Gregory et al. - 2008 
rs13246513 7 80144687 Y 
  
Love-Gregory et al. - 2008 




Kosoy et al. - 2009 





rs854551 7 94765613 
  
Y 
 rs854552 7 94765860 
  
Y 
 rs3917572 7 94767126 
  
Y 
 rs854555 7 94768327 
  
Y 
 rs3917550 7 94772509 
  
Y 
 rs662 7 94775382 
  
Y 
 rs3917538 7 94775829 
  
Y 
 rs3917527 7 94778194 
  
Y 
 rs2074354 7 94778523 
  
Y 
 rs2299257 7 94780701 
  
Y 
 rs854560 7 94784020 
  
Y 
 rs3917498 7 94784191 
  
Y 
 rs854561 7 94784953 
  
Y 
 rs3917490 7 94786777 
  
Y 
 rs2049649 7 94787265 
  
Y 
 rs2299260 7 94787473 
  
Y 
 rs2299261 7 94787599 
  
Y 
 rs854568 7 94787737 
  
Y 
 rs2299262 7 94787864 
  
Y 
 rs854569 7 94787991 
  
Y 
 rs2237583 7 94788113 
  
Y 
 rs3917481 7 94788701 
  
Y 
 rs854571 7 94792555 
  
Y 
 rs854572 7 94792632 
  
Y 
 rs854573 7 94792799 
  
Y 
 rs17166818 7 94796564 
  
Y 
 rs13228784 7 94798761 
  
Y 




Kosoy et al. - 2009 
rs4727479 7 100552387 
  
Y 
 rs6956010 7 100553755 
  
Y 
 rs2227631 7 100556258 
  
Y 
 rs2227667 7 100561469 
  
Y 
 rs2227672 7 100562406 
  
Y 
 rs2227692 7 100565964 
  
Y 
 rs1050955 7 100569180 
  
Y 
 rs757716 7 100574122 
  
Y 




Kosoy et al. - 2009 




Kosoy et al. - 2009 
rs2373962 7 150311910 
  
Y 
 rs2373961 7 150312143 
  
Y 
 rs10277237 7 150314277 
  
Y 
 rs1799983 7 150327044 
  
Y 
 rs3918186 7 150333365 
  
Y 
 rs3918188 7 150333714 
  
Y 
 rs1808593 7 150339235 
  
Y 
 rs7830 7 150340504 
  
Y 
 rs2373929 7 150345745 
  
Y 




Kosoy et al. - 2009 




Kosoy et al. - 2009 
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rs7819412 8 11082571 Y 
  
Kathiresan et al. - 2009 




Kosoy et al. - 2009 
rs17091742 8 19840410 
  
Y 
 rs1800590 8 19840951 Y 
  
Knoblauch et al. - 2004 
rs1534649 8 19843921 
  
Y 
 rs1031045 8 19845392 Y 
  
Knoblauch et al. - 2004 
rs3779788 8 19847373 
  
Y 
 rs343 8 19855067 
  
Y 
 rs249 8 19855286 
  
Y 
 rs253 8 19855697 Y 
  
Knoblauch et al. - 2004 
rs264 8 19857460 
  
Y 
 rs268 8 19857809 Y 
  
Knoblauch et al. - 2004 
rs270 8 19857956 Y 
  
Knoblauch et al. - 2004, Morabia et al. - 2003 
rs285 8 19859469 Y 
  
Knoblauch et al. - 2004, O'Donnell et al. - 2007 
rs320 8 19863357 Y 
  
Bauerfeind et al. - 2006, Knoblauch et al. - 2004 




rs328 8 19864004 Y 
  
Bauerfeind et al. - 2006, Kathiresan et al. - 2008, Knoblauch et 
al. - 2004, Morabia et al. - 2003 
rs3289 8 19867472 Y 
  
Knoblauch et al. - 2004 
rs11570892 8 19867897 
  
Y 
 rs13702 8 19868772 
  
Y 
 rs2197089 8 19870653 Y 
  
Willer et al. - 2008 
rs10096633 8 19875201 Y 
  
Aulchenko et al. - 2009, Sabatti et al. - 2009 
rs17091872 8 19876257 
  
Y 
 rs10097668 8 19878009 
  
Y 
 rs12678919 8 19888502 Y 
  
Kathiresan et al. - 2009, Willer et al. - 2008 
rs10503669 8 19891970 Y 
  
Willer et al. - 2008 
rs17489268 8 19896325 Y 
  
Samani et al. - 2007 
rs17411031 8 19896590 Y 
  
Samani et al. - 2007 
rs2083637 8 19909455 Y 
  
Aulchenko et al. - 2009 
rs894210 8 19910123 Y 
  
Kathiresan et al. - 2009 
rs765547 8 19910554 Y 
   rs6993414 8 19947198 Y 
  
Willer et al. - 2008 
rs6586891 8 19958878 Y 
  
Willer et al. - 2008 




Kosoy et al. - 2009 




Kosoy et al. - 2009 
rs9642976 8 103185175 Y 




Kosoy et al. - 2009 
rs13268726 8 126082315 
  
Y 
 rs3750236 8 126093234 
  
Y 
 rs9297708 8 126100653 
  
Y 
 rs10103274 8 126100936 
  
Y 
 rs9297709 8 126102377 
  
Y 
 rs4559257 8 126501167 
  
Y 
 rs4871593 8 126506812 
  
Y 
 rs2385110 8 126508511 
  
Y 
 rs10956245 8 126509542 
  
Y 
 rs4871594 8 126511247 
  
Y 
 rs2980874 8 126513970 
  
Y 





rs17405319 8 126518588 
  
Y 




rs17321515 8 126555591 Y 
  
Aulchenko et al. - 2009, Kathiresan et al. - 2008, Willer et al. - 
2008 
rs2954029 8 126560154 Y 
  
Kathiresan et al. - 2009, Willer et al. - 2008 
rs6987702 8 126573908 Y 
  
Aulchenko et al. - 2009 




Kosoy et al. - 2009 
rs4736319 8 143981882 
  
Y 
 rs6471580 8 143983703 
  
Y 
 rs4736358 8 143984312 
  
Y 
 rs4536 8 143992763 
  
Y 
 rs6414 8 143993436 
  
Y 




Kosoy et al. - 2009 
rs471364 9 15279578 Y 
  
Kathiresan et al. - 2009 
rs7041637 9 21951866 
  
Y 
 rs3731239 9 21964218 
  
Y 
 rs2811709 9 21970151 
  
Y 
 rs3731211 9 21976847 
  
Y 
 rs3731208 9 21977155 
  
Y 
 rs575427 9 22001477 
  
Y 
 rs545226 9 22002422 
  
Y 
 rs7044859 9 22008781 Y 
  
Samani et al. - 2007 
rs518394 9 22009673 
  
Y 
 rs496892 9 22014351 Y 
   rs10965215 9 22019445 
  
Y 
 rs564398 9 22019547 
  
Y 
 rs7865618 9 22021005 Y 
  
Samani et al. - 2007 
rs17694493 9 22031998 
  
Y 
 rs12352425 9 22032086 
  
Y 
 rs13290048 9 22034804 
  
Y 
 rs11790231 9 22043591 
  
Y 
 rs1011970 9 22052134 
  
Y 
 rs10811650 9 22057593 
  
Y 
 rs4977756 9 22058652 
  
Y 
 rs16905599 9 22059144 
  
Y 
 rs12555547 9 22062040 
  
Y 
 rs1412832 9 22067543 
  
Y 
 rs16905613 9 22070363 
  
Y 
 rs10116277 9 22071397 Y 
  
Helgadottir et al. - 2008 
rs10965227 9 22071796 
  
Y 
 rs1547705 9 22072375 
  
Y 
 rs1333040 9 22073404 Y 
  
Helgadottir et al. - 2007, 2008 
rs10757274 9 22086055 Y 
  
Helgadottir et al. - 2008 
rs2383206 9 22105026 Y 
  
McPherson et al. - 2007 
rs2383207 9 22105959 Y 
  
Helgadottir et al. - 2007, 2008 
rs10757278 9 22114477 Y 
  
Helgadottir et al. - 2007, 2008 
rs1333049 9 22115503 Y 
  
Helgadottir et al. - 2008, Willer et al. - 2008 
rs10811661 9 22124094 Y 
  
Helgadottir et al. - 2008 
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rs10519 9 98911550 Y 
  
Levy et al. - 2007, O'Donnell et al. - 2007 
rs1323432 9 103402758 Y 
  
Willer et al. - 2008 
rs2482430 9 106579173 
  
Y 
 rs2482432 9 106582993 
  
Y 
 rs4149338 9 106585724 
  
Y 
 rs1331924 9 106587443 
  
Y 
 rs2740485 9 106588314 
  
Y 
 rs4149337 9 106588639 
  
Y 
 rs4149336 9 106590460 
  
Y 
 rs2740484 9 106591001 
  
Y 
 rs4149335 9 106591547 
  
Y 
 rs2740481 9 106596238 
  
Y 
 rs2740479 9 106603258 
  
Y 
 rs1999431 9 106604497 
  
Y 
 rs2066716 9 106608526 Y 
  
Bauerfeind et al. - 2006, Knoblauch et al. - 2004 
rs2297409 9 106616067 
  
Y 
 rs2254884 9 106621570 
  
Y 
 rs4149313 9 106626574 Y 
  
Bauerfeind et al. - 2006, Knoblauch et al. - 2004 
rs2066717 9 106631299 
  
Y 
 rs2515629 9 106634185 
  
Y 
 rs2297398 9 106638705 
  
Y 
 rs6479282 9 106641333 
  
Y 
 rs12235875 9 106641446 
  
Y 
 rs2274873 9 106642499 
  
Y 
 rs2472448 9 106644328 
  
Y 
 rs914544 9 106647033 
  
Y 
 rs4149290 9 106651648 
  
Y 
 rs2253174 9 106660153 
  
Y 
 rs2230806 9 106660688 Y 
  
Bauerfeind et al. - 2006, Knoblauch et al. - 2004 
rs2230805 9 106663850 
  
Y 
 rs4149281 9 106666210 
  
Y 
 rs4743764 9 106668925 
  
Y 
 rs1929842 9 106673444 
  
Y 
 rs1929841 9 106673546 
  
Y 
 rs2000069 9 106675690 
  
Y 
 rs1999429 9 106680607 Y 
  
Knoblauch et al. - 2004 
rs3904997 9 106685830 
  
Y 
 rs11789603 9 106686840 
  
Y 
 rs4149268 9 106687041 Y 
  
Willer et al. - 2008 
rs3890182 9 106687476 Y 
  
Kathiresan et al. - 2008, 2008 
rs3847300 9 106688251 
  
Y 
 rs3847303 9 106688473 
  
Y 
 rs3905000 9 106696891 Y 
  
Aulchenko et al. - 2009 
rs3847305 9 106697074 
  
Y 
 rs2740491 9 106698206 
  
Y 
 rs1883025 9 106704122 Y 
  
Kathiresan et al. - 2009 
rs3758294 9 106704636 
  
Y 
 rs2740487 9 106704782 
  
Y 
 rs1800978 9 106705799 Y 
  
Knoblauch et al. - 2004 
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rs2740486 9 106706334 
  
Y 
 rs3905001 9 106707885 
  
Y 
 rs2575879 9 106708646 Y 
  
Bauerfeind et al. - 2006, Knoblauch et al. - 2004 
rs2777794 9 106708707 
  
Y 
 rs4149265 9 106712319 
  
Y 
 rs2437818 9 106715243 
  
Y 
 rs4149263 9 106717110 
  
Y 
 rs4149261 9 106718099 
  
Y 
 rs2515618 9 106718618 
  
Y 
 rs10991410 9 106719021 
  
Y 
 rs10512335 9 106720460 
  
Y 
 rs2515616 9 106721816 
  
Y 
 rs2791952 9 106722338 
  
Y 
 rs2515614 9 106724139 
  
Y 
 rs10991413 9 106724240 
  
Y 
 rs10991414 9 106725410 
  
Y 
 rs2472377 9 106726925 
  
Y 
 rs2472507 9 106727014 
  
Y 
 rs10991416 9 106727519 
  
Y 
 rs1800977 9 106730271 Y 
  
Knoblauch et al. - 2004 
rs2422493 9 106730816 Y 
  
Bauerfeind et al. - 2006, Knoblauch et al. - 2004 
rs2472493 9 106735669 
  
Y 
 rs4452883 9 116819395 
  
Y 
 rs3789875 9 116835109 
  
Y 
 rs12347433 9 116837418 
  
Y 




Kosoy et al. - 2009 
rs10759930 9 119501442 
  
Y 
 rs2770150 9 119502960 
  
Y 
 rs1927907 9 119512585 
  
Y 
 rs5030717 9 119513655 
  
Y 
 rs2149356 9 119514020 
  
Y 
 rs1927906 9 119519936 
  
Y 
 rs7037117 9 119523484 
  
Y 
 rs913930 9 119523830 
  
Y 
 rs7045953 9 119525616 
  
Y 
 rs10759934 9 119528817 
  
Y 
 rs4837960 9 124163792 
  
Y 
 rs16911652 9 124168568 
  
Y 
 rs1213266 9 124176705 
  
Y 
 rs10306135 9 124177516 
  
Y 
 rs3842788 9 124180027 
  
Y 
 rs10306148 9 124183205 
  
Y 
 rs4273915 9 124185150 
  
Y 
 rs3842798 9 124185564 
  
Y 
 rs1771782 9 124189312 
  
Y 
 rs10306202 9 124199342 
  
Y 
 rs12001465 9 131536497 
  
Y 
 rs4636306 9 131536838 
  
Y 





rs2302821 9 131541702 
  
Y 
 rs11788591 9 131542622 
  
Y 
 rs10739757 9 131547731 
  
Y 
 rs10448290 9 131550187 
  
Y 
 rs10988493 9 131551777 
  
Y 
 rs7873087 9 131555776 
  
Y 
 rs10988497 9 131559219 
  
Y 
 rs3844048 9 131562090 
  
Y 
 rs6478915 9 131564271 
  
Y 




Kosoy et al. - 2009 
rs501120 10 44073873 Y 
   rs3780894 10 45194666 
  
Y 
 rs2228064 10 45198056 
  
Y 
 rs4948671 10 45200062 
  
Y 
 rs7918542 10 45216257 
  
Y 
 rs7099684 10 45217161 
  
Y 
 rs7917687 10 45217867 
  
Y 
 rs3780900 10 45218919 
  
Y 
 rs2115819 10 45221095 
  
Y 
 rs10900213 10 45224720 
  
Y 
 rs11239524 10 45232777 
  
Y 
 rs3780901 10 45237382 
  
Y 
 rs3780902 10 45239063 
  
Y 
 rs17157784 10 45240820 
  
Y 
 rs3780906 10 45241988 
  
Y 
 rs2279435 10 45243534 
  
Y 
 rs1565097 10 45244262 
  
Y 
 rs1487562 10 45248828 
  
Y 
 rs901681 10 45254535 
  
Y 
 rs2291427 10 45256230 
  
Y 
 rs7896431 10 45257429 
  
Y 
 rs10751383 10 45257998 
  
Y 
 rs2288619 10 45259824 
  
Y 




Kosoy et al. - 2009 




Kosoy et al. - 2009 
rs11185790 10 91362513 Y 
  
Sabatti et al. - 2009 
rs1075374 10 91366955 Y 
  
Sabatti et al. - 2009 
rs4244285 10 96531606 Y 
   rs1135654 10 96721871 Y 




Kosoy et al. - 2009 




Kosoy et al. - 2009 




Kosoy et al. - 2009 




Kosoy et al. - 2009 




Kosoy et al. - 2009 
rs2070850 11 46698071 
  
Y 
 rs2070852 11 46701501 
  
Y 
 rs3136456 11 46702437 
  
Y 
 rs2167079 11 47226831 Y 
  
Sabatti et al. - 2009 





rs10838681 11 47231640 
  
Y 
 rs7120118 11 47242866 Y 
  
Sabatti et al. - 2009 
rs326217 11 47259851 
  
Y 
 rs3816724 11 47268621 
  
Y 
 rs10838687 11 47269468 
  
Y 
 rs10838689 11 47291100 
  
Y 
 rs10838692 11 47301676 
  
Y 
 rs11039183 11 47303516 
  
Y 
 rs3729953 11 47315573 
  
Y 
 rs7395662 11 48475469 Y 
  
Aulchenko et al. - 2009 
rs16906158 11 49127350 
  
Y 
 rs2299650 11 49130583 
  
Y 
 rs202719 11 49149266 
  
Y 
 rs202700 11 49173275 
  
Y 
 rs202676 11 49184196 
  
Y 
 rs639572 11 49190997 
  
Y 
 rs12099184 11 49195312 
  
Y 
 rs174537 11 61309256 Y 
  
Sabatti et al. - 2009 
rs102275 11 61314379 Y 
  
Kathiresan et al. - 2009, Sabatti et al. - 2009 
rs174546 11 61326406 Y 
  
Sabatti et al. - 2009 
rs174547 11 61327359 Y 
  
Kathiresan et al. - 2009 
rs174556 11 61337211 Y 
  
Sabatti et al. - 2009 
rs174570 11 61353788 Y 
  
Aulchenko et al. - 2009 
rs1535 11 61354548 Y 
  
Sabatti et al. - 2009 
rs2845573 11 61358484 
  
Y 
 rs174575 11 61358579 
  
Y 
 rs2524299 11 61361358 
  
Y 
 rs174578 11 61362075 
  
Y 
 rs174602 11 61380990 
  
Y 
 rs498793 11 61381281 
  
Y 
 rs526126 11 61381461 
  
Y 
 rs174605 11 61383497 
  
Y 
 rs174616 11 61385698 
  
Y 
 rs1000778 11 61411881 
  
Y 
 rs174455 11 61412693 
  
Y 
 rs174468 11 61420267 
  
Y 
 rs13966 11 61421568 
  
Y 




Kosoy et al. - 2009 
rs1447352 11 92362409 Y 
  
Sabatti et al. - 2009 
rs17293642 11 102160138 
  
Y 
 rs559518 11 102161289 
  
Y 
 rs11225422 11 102161528 
  
Y 
 rs2408489 11 102162896 
  
Y 
 rs7125062 11 102168713 
  
Y 
 rs7125320 11 102168918 
  
Y 
 rs11225426 11 102169801 
  
Y 
 rs996999 11 102172273 
  
Y 
 rs10488 11 102173232 
  
Y 





rs1144393 11 102174619 
  
Y 
 rs1155764 11 102177659 
  
Y 
 rs484915 11 102178458 
  
Y 
 rs7926920 11 102203934 
  
Y 
 rs12277638 11 102206435 
  
Y 
 rs650108 11 102213997 
  
Y 
 rs646910 11 102214732 
  
Y 
 rs522616 11 102220258 
  
Y 
 rs613804 11 102225631 
  
Y 
 rs626750 11 102226155 
  
Y 
 rs486394 11 116031532 Y 
  
Willer et al. - 2008 
rs2000571 11 116090743 Y 
  
Willer et al. - 2008 
rs12272004 11 116108934 Y 
  
Aulchenko et al. - 2009 
rs10466588 11 116115459 
  
Y 
 rs9326246 11 116116943 
  
Y 
 rs180349 11 116117037 
  
Y 
 rs17092646 11 116117174 
  
Y 
 rs180346 11 116117869 
  
Y 
 rs28927680 11 116124283 Y 
  
Kathiresan et al. - 2008 
rs17440396 11 116126980 
  
Y 
 rs12421652 11 116131085 
  
Y 
 rs2075295 11 116133611 
  
Y 
 rs964184 11 116154127 Y 
  
Kathiresan et al. - 2009, Willer et al. - 2008 
rs12286037 11 116157417 Y 
  
Willer et al. - 2008 
rs4417316 11 116157511 
  
Y 
 rs2072560 11 116167036 Y 
  
Knoblauch et al. - 2004 
rs3135506 11 116167617 Y 
  
Hubayek et al. - 2009, Knoblauch et al. - 2004 




rs662799 11 116168917 Y 
  
Hubayek et al. - 2009, Knoblauch et al. - 2004, Willer et al. - 
2008 
rs17120035 11 116169061 
  
Y 
 rs1729410 11 116170871 
  
Y 
 rs633389 11 116172547 
  
Y 
 rs6589567 11 116175886 
  
Y 
 rs2266789 11 116180027 Y 
  
Knoblauch et al. - 2004 
rs7396851 11 116189374 Y 
   rs675 11 116196885 Y 
  
Aulchenko et al. - 2009, Knoblauch et al. 2004 
rs5100 11 116197904 
  
Y 
 rs5092 11 116198674 Y 
  
Knoblauch et al. - 2004 
rs5091 11 116199215 
  
Y 
 rs2542051 11 116202948 Y 
  
Knoblauch et al. - 2004 
rs2854116 11 116205379 Y 
  
Knoblauch et al. - 2004 
rs4520 11 116206745 Y 
  
Knoblauch et al. - 2004 
rs5128 11 116208850 Y 
  
Hubayek et al. - 2009, Knoblauch et al. - 2004 
rs5081 11 116211556 Y 
  
Knoblauch et al. - 2004 
rs5070 11 116213230 Y 
  
Bauerfeind et al. - 2006, Knoblauch et al. - 2004 
rs1799837 11 116213468 Y 
  
Knoblauch et al. - 2004 
rs10892044 11 116272109 Y 
  
Kathiresan et al. - 2009 
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Kosoy et al. - 2009 




Kosoy et al. - 2009 
rs10778213 12 102019281 
  
Y 




Kosoy et al. - 2009 
rs7953327 12 108466918 
  
Y 
 rs888194 12 108471301 
  
Y 
 rs2241201 12 108476515 
  
Y 
 rs877710 12 108478359 
  
Y 
 rs11067253 12 108482361 
  
Y 
 rs754180 12 108488451 
  
Y 
 rs17183465 12 108514133 
  
Y 




Kosoy et al. - 2009 
rs2650000 12 119873345 Y 
  
Kathiresan et al. - 2009, Sabatti et al. - 2009 
rs7310409 12 119909244 
  
Y 
 rs1169300 12 119915608 
  
Y 
 rs11057811 12 123823319 
  
Y 
 rs838878 12 123826598 
  
Y 
 rs701106 12 123831589 
  
Y 
 rs838894 12 123835449 
  
Y 
 rs2272310 12 123837631 
  
Y 
 rs9919713 12 123838716 
  
Y 
 rs5888 12 123850701 Y 
  
Morabia et al. - 2003 
rs989892 12 123853169 
  
Y 
 rs838900 12 123859550 
  
Y 
 rs11057820 12 123862917 
  
Y 
 rs10846739 12 123863377 
  
Y 
 rs4765615 12 123865783 
  
Y 
 rs2343394 12 123866504 
  
Y 
 rs1902569 12 123869957 
  
Y 
 rs10846745 12 123878565 
  
Y 
 rs11057841 12 123882696 
  
Y 
 rs12581963 12 123883078 
  
Y 
 rs10744181 12 123883183 
  
Y 
 rs10773107 12 123883344 
  
Y 
 rs10744182 12 123883535 
  
Y 
 rs7954519 12 123886108 
  
Y 
 rs4765623 12 123886803 
  
Y 
 rs12582221 12 123889193 
  
Y 
 rs7306660 12 123893337 
  
Y 
 rs11057852 12 123894779 
  
Y 
 rs10773111 12 123898908 
  
Y 
 rs11615630 12 123907823 
  
Y 
 rs7139401 12 123911401 
  
Y 
 rs4379922 12 123917069 
  
Y 
 rs10846760 12 123917725 
  
Y 
 rs6488950 12 123920056 
  
Y 
 rs6490506 13 19472373 Y 
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rs4076128 13 30203143 
  
Y 
 rs4073261 13 30204646 
  
Y 
 rs4769055 13 30207830 
  
Y 
 rs4075131 13 30208919 
  
Y 
 rs9578196 13 30209557 
  
Y 
 rs10507391 13 30210096 
  
Y 
 rs12429692 13 30210178 
  
Y 
 rs4769873 13 30210689 
  
Y 
 rs4503649 13 30212174 
  
Y 
 rs3885907 13 30212455 
  
Y 
 rs10162089 13 30214738 
  
Y 
 rs12431114 13 30215452 
  
Y 
 rs4254165 13 30215878 
  
Y 
 rs3803277 13 30216308 
  
Y 
 rs9671124 13 30222253 
  
Y 
 rs9579648 13 30225032 
  
Y 
 rs9315048 13 30225840 
  
Y 
 rs9508833 13 30229154 
  
Y 
 rs4769875 13 30229915 
  
Y 
 rs4769058 13 30231431 
  
Y 
 rs9315051 13 30234177 
  
Y 
 rs3935644 13 30235640 
  
Y 
 rs4769060 13 30235877 
  
Y 
 rs9670198 13 30242453 
  
Y 
 rs9579653 13 30242712 
  
Y 
 rs4319601 13 30245122 
  
Y 
 rs4769062 13 30245221 
  
Y 
 rs4238139 13 30245589 
  
Y 




Kosoy et al. - 2009 




Kosoy et al. - 2009 
rs9521430 13 109027997 Y 




Kosoy et al. - 2009 




Kosoy et al. - 2009 




Kosoy et al. - 2009 




Kosoy et al. - 2009 




Kosoy et al. - 2009 




Kosoy et al. - 2009 
rs10142528 14 91400543 
  
Y 
 rs7155616 14 91402475 
  
Y 
 rs3825687 14 91403364 
  
Y 
 rs929609 14 91406742 
  
Y 
 rs929610 14 91406906 
  
Y 
 rs2430340 14 91407527 
  
Y 
 rs7143288 14 91407630 
  
Y 
 rs917907 14 91409400 
  
Y 
 rs2267989 14 91409603 
  
Y 
 rs10484030 14 91412338 
  
Y 
 rs2498847 14 91414053 
  
Y 





rs966382 14 91421405 
  
Y 
 rs1006856 14 91423715 
  
Y 
 rs2430353 14 91424870 
  
Y 
 rs2267994 14 91426699 
  
Y 
 rs2243400 14 91428673 
  
Y 
 rs2267996 14 91429478 
  
Y 
 rs917908 14 91433539 
  
Y 
 rs2430363 14 91434804 
  
Y 
 rs741198 14 91437164 
  
Y 
 rs2300137 14 91439777 
  
Y 
 rs1861085 14 91440987 
  
Y 
 rs2160079 14 91444158 
  
Y 
 rs2160080 14 91444240 
  
Y 
 rs2249946 14 91453895 
  
Y 
 rs17732513 14 91456132 
  
Y 
 rs2430368 14 91457294 
  
Y 
 rs2284340 14 91458800 
  
Y 
 rs10149504 14 91463925 
  
Y 
 rs2430373 14 91464063 
  
Y 
 rs12586793 14 91471387 
  
Y 
 rs2474028 14 91473413 
  
Y 
 rs3783937 14 91477446 
  
Y 
 rs13379081 14 91478062 
  
Y 
 rs3814835 14 91484133 
  
Y 
 rs2474030 14 91485073 
  
Y 




Kosoy et al. - 2009 




Kosoy et al. - 2009 




Kosoy et al. - 2009 
rs2624265 15 36935941 Y 
  
Sabatti et al. - 2009 
rs4775041 15 56461987 Y 
  
Aulchenko et al. - 2009, Willer et al. - 2008 
rs10468017 15 56465804 Y 
  
Kathiresan et al. - 2009, Willer et al. - 2008 
rs1532085 15 56470658 Y 
  
Aulchenko et al. - 2009, Sabatti et al. - 2009 
rs723967 15 56483592 Y 
  
Knoblauch et al. - 2004 
rs792902 15 56503336 
  
Y 
 rs375372 15 56503907 
  
Y 
 rs17190503 15 56504314 
  
Y 
 rs16940262 15 56504720 
  
Y 
 rs1373657 15 56505054 
  
Y 
 rs417344 15 56505211 
  
Y 
 rs7163052 15 56505522 
  
Y 
 rs7170361 15 56506290 
  
Y 




rs1800588 15 56510967 Y 
  
Bauerfeind et al. - 2006, Knoblauch et al. - 2004, Kathiresan et 
al. - 2008, 2008 
rs2070895 15 56511231 Y 
  
Bauerfeind et al. - 2006, Kathiresan et al. - 2009, Morabia et al. 
- 2003 
rs11631342 15 56511675 
  
Y 
 rs6494005 15 56511816 
  
Y 
 rs8034802 15 56512084 
  
Y 
 rs261334 15 56514036 
  
Y 
 rs261332 15 56514617 Y 
  
Kaess et al. - 2011, Willer et al. - 2008 
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rs11636642 15 56514793 
  
Y 
 rs17190517 15 56516436 
  
Y 
 rs17301739 15 56517931 
  
Y 
 rs12914035 15 56518181 
  
Y 
 rs17301746 15 56518687 
  
Y 
 rs166362 15 56520804 
  
Y 
 rs261337 15 56522741 
  
Y 
 rs497381 15 56524330 
  
Y 
 rs17269278 15 56528045 
  
Y 
 rs485671 15 56528426 
  
Y 
 rs572410 15 56528676 
  
Y 
 rs8041059 15 56531001 
  
Y 
 rs3825776 15 56534122 
  
Y 
 rs934297 15 56540026 
  
Y 
 rs11631153 15 56541284 
  
Y 
 rs17301781 15 56542168 
  
Y 
 rs12902119 15 56543846 
  
Y 
 rs12148704 15 56545698 
  
Y 
 rs12593008 15 56548267 
  
Y 
 rs7182229 15 56552475 
  
Y 
 rs1968685 15 56555046 
  
Y 
 rs12914552 15 56556753 
  
Y 
 rs4775053 15 56556875 
  
Y 
 rs17190594 15 56558376 
  
Y 
 rs1869137 15 56565704 
  
Y 
 rs11856322 15 56567305 
  
Y 
 rs1973028 15 56578646 
  
Y 
 rs16940372 15 56582805 
  
Y 
 rs16940379 15 56583537 
  
Y 
 rs1869144 15 56584592 Y 
  
Knoblauch et al. - 2004 
rs1869145 15 56584791 
  
Y 
 rs12324517 15 56588058 
  
Y 
 rs4613005 15 56588526 
  
Y 
 rs7174210 15 56596785 
  
Y 
 rs2899632 15 56599161 
  
Y 
 rs8028759 15 56599491 
  
Y 
 rs9652472 15 56606075 
  
Y 
 rs12899928 15 56606843 
  
Y 
 rs1968689 15 56610077 
  
Y 
 rs4775073 15 56613924 
  
Y 
 rs17301822 15 56614915 
  
Y 
 rs11071387 15 56615876 
  
Y 
 rs8035006 15 56616507 
  
Y 
 rs1971544 15 56616743 
  
Y 
 rs2233741 15 56618655 
  
Y 
 rs6078 15 56621285 Y 
  
Bauerfeind et al. - 2006, Knoblauch et al. - 2004 
rs2242062 15 56621683 
  
Y 
 rs690 15 56622033 Y 
  
Bauerfeind et al. - 2006, Knoblauch et al. - 2004 





rs11852861 15 56623600 
  
Y 
 rs12592139 15 56624230 
  
Y 
 rs12592127 15 56624381 
  
Y 
 rs4775075 15 56625056 
  
Y 
 rs6082 15 56625249 Y 
  
Bauerfeind et al. - 2006, Knoblauch et al. - 2004 
rs6084 15 56625330 Y 
  
Bauerfeind et al. - 2006, Knoblauch et al. - 2004, Morabia et al. 
- 2003 
rs2242064 15 56626564 
  
Y 
 rs7165654 15 56627331 
  
Y 
 rs7166788 15 56629028 
  
Y 
 rs11632627 15 56630175 
  
Y 
 rs871804 15 56631506 
  
Y 
 rs7178362 15 56634555 
  
Y 
 rs7170227 15 56641879 
  
Y 
 rs17301864 15 56642504 
  
Y 
 rs3829460 15 56645237 
  
Y 
 rs6074 15 56648255 Y 
  
Bauerfeind et al. - 2006, Knoblauch et al. - 2004 
rs17228212 15 65245693 Y 
  
Samani et al. - 2007 




Kosoy et al. - 2009 




Kosoy et al. - 2009 
rs9806366 15 99620480 Y 




Kosoy et al. - 2009 




Kosoy et al. - 2009 




Kosoy et al. - 2009 
rs12596776 16 55476849 Y 
  
Willer et al. - 2008 
rs9989419 16 55542640 Y 
  
Kathiresan et al. - 2009 
rs173539 16 55545545 Y 
  
Kathiresan et al. - 2009 
rs6499863 16 55549518 
  
Y 




rs3764261 16 55550825 Y 
  
Kaess et al. - 2011, Willer et al. - 2008, Thompson et al. - 
2007, Sabatti et al. - 2009 
rs4783961 16 55552395 Y 
  
Bauerfeind et al. - 2006, Knoblauch et al. - 2004, Thompson et 
al. - 2007 




rs1800776 16 55552735 Y 
  
Bauerfeind et al. - 2006, Knoblauch et al. - 2004, Boekholdt et 
al. - 2003 
rs711752 16 55553712 Y 
  
Boekholdt et al. - 2003, Knoblauch et al. - 2004 
rs708272 16 55553789 Y 
  
Boekholdt et al. - 2003, Knoblauch et al. - 2004, Thompson et 
al. - 2007 
rs1864163 16 55554734 Y 
  
Willer et al. - 2008 
rs820299 16 55557785 
  
Y 
 rs11076174 16 55560647 
  
Y 
 rs7205804 16 55562390 Y 
  
Bauerfeind et al. - 2006, Morabia et al. - 2003 
rs1532625 16 55562802 Y 
  
Bauerfeind et al. - 2006, Knoblauch et al. - 2004, Boekholdt et 
al. - 2003 
rs1532624 16 55562980 Y 
  
Aulchenko et al. - 2009 
rs11076175 16 55563879 
  
Y 
 rs289714 16 55564952 Y 
  
Boekholdt et al. - 2003, Kathiresan et al. - 2009 
rs289717 16 55566889 
  
Y 
 rs289718 16 55567433 Y 
  
Boekholdt et al. - 2003, Knoblauch et al. - 2004 
rs12720898 16 55568744 
  
Y 
 rs891144 16 55569437 
  
Y 
 rs5880 16 55572592 Y 
  
Boekholdt et al. - 2003, Knoblauch et al. - 2004 
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rs1800774 16 55573046 
  
Y 
 rs5882 16 55573593 Y 
  
Boekholdt et al. - 2003 
rs1800777 16 55574820 Y 
  
Boekholdt et al. - 2003 
rs1801706 16 55575163 Y 
  
Bauerfeind et al. - 2006, Knoblauch et al. - 2004, Boekholdt et 
al. - 2003 
rs289742 16 55575263 
  
Y 
 rs289744 16 55575603 
  
Y 
 rs289745 16 55577033 
  
Y 
 rs1566439 16 55582163 Y 
  
Willer et al. - 2008 




Kosoy et al. - 2009 
rs2271293 16 66459571 Y 
  
Aulchenko et al. - 2009, Kathiresan et al. - 2009 
rs5923 16 66531454 Y 
  
Bauerfeind et al. - 2006, Knoblauch et al. - 2004 
rs4986970 16 66533821 Y 
  
Bauerfeind et al. - 2006, Knoblauch et al. - 2004 
rs1109166 16 66534883 Y 
  
Knoblauch et al. - 2004 
rs255049 16 66570972 Y 
  
Sabatti et al. - 2009 
rs255052 16 66582496 Y 
  
Willer et al. - 2008 
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Kosoy et al. - 2009 
rs9891572 17 2375258 Y 
  
Sabatti et al. - 2009 
rs4790210 17 4475587 
  
Y 
 rs916055 17 4481583 
  
Y 
 rs7217186 17 4486141 
  
Y 
 rs2664593 17 4491881 
  
Y 
 rs748694 17 4496938 
  
Y 
 rs3730340 17 11985108 Y 
   rs4795050 17 23103032 
  
Y 
 rs4795051 17 23103624 
  
Y 
 rs11653716 17 23108659 
  
Y 
 rs7208775 17 23109235 
  
Y 
 rs9906835 17 23113501 
  
Y 
 rs2297516 17 23119857 
  
Y 
 rs9797244 17 23121258 
  
Y 
 rs2248814 17 23124448 
  
Y 
 rs11080344 17 23128638 
  
Y 
 rs4795067 17 23130802 
  
Y 
 rs3729508 17 23133157 
  
Y 
 rs944725 17 23133698 
  
Y 
 rs17722851 17 23134963 
  
Y 
 rs3794764 17 23135555 
  
Y 
 rs16966563 17 23140076 
  
Y 
 rs8072199 17 23140975 
  
Y 
 rs3794766 17 23146048 
  
Y 
 rs3730013 17 23150045 
  
Y 
 rs10459953 17 23151645 
  
Y 
 rs2779248 17 23151959 
  
Y 
 rs11080358 17 23154723 
  
Y 
 rs12150211 17 23158559 
  
Y 
 rs2734299 17 23159085 
  
Y 
 rs11867200 17 29600082 
  
Y 





rs2530797 17 29610207 
  
Y 
 rs991804 17 29611838 
  
Y 
 rs8067673 17 35954741 
  
Y 
 rs3136695 17 35962217 
  
Y 
 rs2023906 17 35967212 
  
Y 
 rs588019 17 35968633 
  
Y 
 rs2290065 17 35969886 
  
Y 
 rs3136685 17 35973325 
  
Y 
 rs7218773 17 42679210 
  
Y 
 rs2056131 17 42688742 
  
Y 
 rs8077375 17 42691151 
  
Y 
 rs16941751 17 42691506 
  
Y 
 rs4525555 17 42692948 
  
Y 
 rs3892084 17 42695420 
  
Y 
 rs7219925 17 42696639 
  
Y 
 rs8074094 17 42703020 
  
Y 
 rs3851806 17 42705918 
  
Y 
 rs7209700 17 42706117 
  
Y 
 rs11868894 17 42708188 
  
Y 
 rs7217214 17 42710226 
  
Y 
 rs2292867 17 42712488 
  
Y 
 rs2292699 17 42717294 
  
Y 
 rs2292700 17 42717422 
  
Y 
 rs2292864 17 42722680 
  
Y 
 rs12603582 17 42732576 
  
Y 
 rs3744453 17 42737869 
  
Y 
 rs3809863 17 42740011 
  
Y 
 rs12600865 17 42748983 
  
Y 
 rs6504833 17 42751086 
  
Y 
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Y 
 rs8082134 17 53707625 
  
Y 
 rs2243828 17 53713883 
  
Y 
 rs2107545 17 53715117 
  
Y 
 rs12452417 17 53722201 
  
Y 
 rs4459609 17 58902680 
  
Y 
 rs4305 17 58911961 
  
Y 
 rs4309 17 58913655 
  
Y 
 rs4311 17 58914495 
  
Y 
 rs4362 17 58927493 
  
Y 
 rs9894286 17 58929764 
  
Y 
 rs4461142 17 58931780 
  
Y 
 rs4267385 17 58937488 
  
Y 
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rs12962061 18 45332909 
  
Y 
 rs2097055 18 45349485 
  
Y 
 rs8093249 18 45351396 
  
Y 
 rs11875600 18 45353184 
  
Y 
 rs12970066 18 45361150 
  
Y 
 rs6507931 18 45367006 
  
Y 
 rs9958734 18 45372396 
  
Y 
 rs17798991 18 45375314 
  
Y 
 rs11664186 18 45375696 
  
Y 
 rs12606544 18 45377235 
  
Y 
 rs4939585 18 45377761 
  
Y 
 rs8099385 18 45380883 
  
Y 
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Y 
 rs3745367 19 7640511 
  
Y 
 rs3745369 19 7641475 
  
Y 
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Y 
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Y 
 rs2967605 19 8375738 Y 
  
Kathiresan et al. - 2009 
rs5030340 19 10243281 
  
Y 
 rs5030390 19 10243537 
  
Y 
 rs5030391 19 10243637 
  
Y 
 rs281432 19 10251658 
  
Y 
 rs5030400 19 10256796 
  
Y 
 rs3093032 19 10257336 
  
Y 
 rs3093030 19 10258403 
  
Y 
 rs1529729 19 11024562 Y 
  
Kathiresan et al. - 2008 
rs6511720 19 11063306 Y 
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al. - 2008 
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rs5930 19 11085265 Y 
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2003 
rs2738446 19 11088326 Y 
  
Kathiresan et al. - 2009 
rs688 19 11088602 Y 
  
Kathiresan et al. - 2008, Wellcome et al. - 2007 
rs5925 19 11091881 Y 
  
Bauerfeind et al. - 2006, Knoblauch et al. - 2004 
rs5927 19 11094941 Y 
  
Boekholdt et al. - 2003, Knoblauch et al. - 2004 
rs2569540 19 11099239 
  
Y 
 rs2738459 19 11099473 
  
Y 
 rs2304182 19 11099877 
  
Y 
 rs6413503 19 11102904 
  
Y 
 rs3826810 19 11103133 
  
Y 









rs1433099 19 11103658 Y 
  
Bauerfeind et al. - 2006, Knoblauch et al. - 2004, Morabia et al. 
2003 
rs10412238 19 19179158 
  
Y 
 rs7250569 19 19185443 
  
Y 
 rs2228603 19 19190924 Y 
  
Kathiresan et al. - 2008, Willer et al. - 2008 
rs1859055 19 19202160 
  
Y 
 rs10424369 19 19206356 
  
Y 
 rs10413995 19 19214000 Y 
   rs10402294 19 19215937 
  
Y 
 rs4808931 19 19219672 
  
Y 
 rs10407933 19 19225319 
  
Y 
 rs10422819 19 19504028 
  
Y 




rs16996148 19 19519472 Y 
  
Aulchenko et al. - 2009, Kathiresan et al. - 2008, Willer et al. - 
2008 
rs17216525 19 19523220 Y 
  
Kathiresan et al. - 2009 
rs4145657 19 19523832 
  
Y 
 rs892023 19 19524850 
  
Y 
 rs8103992 19 19526643 
  
Y 
 rs16996174 19 19569551 
  
Y 
 rs1476459 19 19581028 
  
Y 
 rs10500212 19 19584215 
  
Y 
 rs1054685 19 19595539 
  
Y 
 rs873870 19 19599554 
  
Y 
 rs2304130 19 19650528 Y 
  
Aulchenko et al. - 2009 




Kosoy et al. - 2009 
rs4803750 19 49939467 Y 
  
Sandhu et al. - 2008 
rs10402271 19 50021054 Y 
  
Sandhu et al. - 2008, Willer et al. - 2008 
rs283814 19 50081064 
  
Y 
 rs7254892 19 50081436 
  
Y 
 rs6857 19 50084094 
  
Y 
 rs157580 19 50087106 Y 
  
Aulchenko et al. - 2009, Sabatti et al. - 2009 
rs2075650 19 50087459 Y 
  
Aulchenko et al. - 2009, Sandhu et al. - 2008 
rs8106922 19 50093506 
  
Y 
 rs405509 19 50100676 Y 
  
Bauerfeind et al. - 2006, Knoblauch et al. - 2004 
rs440446 19 50101007 Y 
  
Bauerfeind et al. - 2006, Knoblauch et al. - 2004 
rs769449 19 50101842 
  
Y 
 rs7412 19 50103919 Y 
  
Bauerfeind et al. - 2006, Knoblauch et al. - 2004 
rs439401 19 50106291 Y 
  
Aulchenko et al. - 2009 
rs4420638 19 50114786 Y 
  
Kathiresan et al. - 2008, 2008, 2009, Sandhu et al. - 2008, 
Saxena et al. - 2007, Wellcome et al. - 2007, Willer et al. - 
2008 
rs4803770 19 50119193 
  
Y 
 rs4803771 19 50119488 
  
Y 
 rs7259004 19 50124397 
  
Y 
 rs12721108 19 50139081 
  
Y 
 rs5167 19 50140305 Y 
  
Knoblauch et al. - 2004 
rs5168 19 50140395 
  
Y 
 rs2288911 19 50141124 Y 
  
Knoblauch et al. - 2004 
rs5120 19 50143460 Y 
  
Knoblauch et al. - 2004 
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rs5127 19 50144534 
  
Y 
 rs892101 19 50147298 Y 
  
Knoblauch et al. - 2004 
rs10413089 19 50147428 
  
Y 
 rs204907 19 50153836 
  
Y 
 rs1405655 19 55574431 
  
Y 
 rs3219281 19 55578899 
  
Y 
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Kosoy et al. - 2009 
rs6102059 20 38662198 Y 
  
Kathiresan et al. - 2009 
rs1800961 20 42475778 Y 
  
Kathiresan et al. - 2009 
rs742034 20 43955412 
  
Y 
 rs7270170 20 43960190 
  
Y 
 rs1736493 20 43964041 
  
Y 
 rs11086985 20 43965662 
  
Y 
 rs6073952 20 43970339 
  
Y 
 rs378114 20 43971834 
  
Y 
 rs441346 20 43972899 
  
Y 
 rs2294212 20 43973971 
  
Y 
 rs4810479 20 43978455 
  
Y 
 rs7679 20 44009909 Y 
  
Kathiresan et al. - 2009 
rs6094237 20 44062697 
  
Y 
 rs6065912 20 44065774 
  
Y 
 rs4810482 20 44067957 
  
Y 
 rs3787268 20 44075138 
  
Y 
 rs2250889 20 44075813 
  
Y 
 rs6094238 20 44086514 
  
Y 
 rs6095543 20 47546707 
  
Y 
 rs1393342 20 47548642 
  
Y 
 rs6095546 20 47550362 
  
Y 
 rs5619 20 47554250 
  
Y 
 rs5602 20 47555385 
  
Y 
 rs6090996 20 47567189 
  
Y 
 rs508757 20 47572378 
  
Y 
 rs5628 20 47574089 
  
Y 
 rs11697964 20 47579678 
  
Y 
 rs501908 20 47589174 
  
Y 
 rs12625166 20 47600610 
  
Y 
 rs476496 20 47611191 
  
Y 
 rs927068 20 47611381 
  
Y 
 rs6019902 20 47611620 
  
Y 
 rs477627 20 47613465 
  
Y 
 rs693649 20 47621486 
  
Y 
 rs11905684 20 47624098 
  
Y 
 rs11905590 20 51611297 
  
Y 
 rs2766669 20 51611633 
  
Y 
 rs6126871 20 51615163 
  
Y 
 rs6126872 20 51615982 
  
Y 





rs6091708 20 51622424 
  
Y 
 rs6063966 20 51626495 
  
Y 
 rs3748503 20 51626775 
  
Y 
 rs16998248 20 51631747 
  
Y 
 rs1075390 20 51642245 
  
Y 
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rs741754 21 36143344 Y 




Kosoy et al. - 2009 
rs8128028 21 43339612 
  
Y 
 rs2401193 21 43339836 
  
Y 
 rs11911976 21 43340549 
  
Y 
 rs11909493 21 43340760 
  
Y 
 rs466791 21 43343023 
  
Y 
 rs719037 21 43344056 
  
Y 
 rs11700748 21 43346131 
  
Y 
 rs1051319 21 43346936 
  
Y 
 rs3788050 21 43347732 
  
Y 
 rs2124458 21 43348749 
  
Y 
 rs11203172 21 43353184 
  
Y 
 rs4920037 21 43354960 
  
Y 
 rs1789953 21 43356005 
  
Y 
 rs234705 21 43356841 
  
Y 
 rs11701048 21 43364494 
  
Y 
 rs1788484 21 43370010 
  
Y 
 rs2850146 21 43373655 
  
Y 
 rs4818909 21 44588388 Y 
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Kosoy et al. - 2009 
rs4822056 22 40549800 
  
Y 
 rs7285782 22 40554964 
  
Y 
 rs2267439 22 40567715 
  
Y 
 rs7287886 22 40567973 
  
Y 
 rs714015 22 40589044 
  
Y 
 rs4822063 22 40606688 
  
Y 
 rs4822064 22 40609452 
  
Y 
 rs13055841 22 40609599 
  
Y 
 rs2269658 22 40610564 
  
Y 
 rs9623468 22 40611240 
  
Y 
 rs17002737 22 40611958 
  
Y 
 rs2267443 22 40617400 
  
Y 
 rs12157312 22 40620123 
  
Y 
 rs2269660 22 40622869 
  
Y 
 rs17379759 22 40629481 
  
Y 
 rs5031002 X 66859350 Y 
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